DAFTAR PUSTAKA

Abbas, A. K., Lichtman, A. H. and Pillai, S. (2018) *Cellular and Molecular Immunology*. Ninth. Philadelphia: Elsevier Inc.

Abbott, N. J. *et al.* (2010) 'Structure and function of the blood – brain barrier', *Neurobiology of Disease*, 37(1), pp. 13–25. doi: 10.1016/j.nbd.2009.07.030.

Abulafia, D. P. *et al.* (2009) 'Inhibition of the inflammasome complex reduces the inflammatory response after thromboembolic stroke in mice', *Journal of Cerebral Blood Flow {\&} Metabolism*, 29(3), pp. 534–544. doi: 10.1038/jcbfm.2008.143.

Abzhandadze, T. *et al.* (2018) 'Feasibility of Cognitive Functions Screened With the Montreal Cognitive Assessment in Determining ADL Dependence Early After Stroke', *Frontiers in Neurology*, 9, p. 705. doi: 10.3389/fneur.2018.00705.

Alers, S. and Wesselborg, S. (2012) 'Role of AMPK-mTOR-Ulk1/2 in the Regulation of Autophagy: Cross Talk, Shortcuts, and Feedbacks', *Molecular and Cellular Biology*, 32(1), pp. 2–11. doi: 10.1128/MCB.06159-11.

Antonaros, F. *et al.* (2019) 'MTHFR C677T polymorphism analysis: A simple, effective restriction enzyme - based method improving previous protocols', *Molecular Genetics and Genomic Medicine*, 7, p. e628. doi: 10.1002/mgg3.628.

Arina, C. A. *et al.* (2019) 'The Role of Polymorphism Gen Methylene Tetra Hydrofolate Reductase (MTHFR) C677T in Ischaemic Stroke Patients with and Without Hypertension', *Open Access Macedonian Journal of Medical Sciences*, 7(1), pp. 29–32.

Arsene, D. *et al.* (2011) 'C677T and A1298C methylenetetrahydropholate involved in ischemic stroke', *Romanian Journal of Morphology and Embryology*, 52(4), pp. 1203–1207.

Arsic, S. *et al.* (2015) 'Correlation between Functional Independence and

Quality of Executive Functions in Stroke Patients', *Turkish Journal of Physical Medicine and Rehabilitation*, 61, pp. 333–338. doi: 10.5152/tftrd.2015.25932.

Bano, D. and Nicotera, P. (2007) 'Ca2_ Signals and Neuronal Death in Brain Ischemia', *Stroke*, 38(2 Suppl), pp. 674–676.

Barroso, M., Handy, D. E. and Castro, R. (2017) 'The Link Between Hyperhomocysteinemia and Hypomethylation : Implications for Cardiovascular Disease', *Journal of Inborn Errors of Metabolism {\&} Screening*, 5, pp. 1–15. doi: 10.1177/2326409817698994.

Barulli, D. and Stern, Y. (2013) 'Efficiency, capacity, compensation, maintenance, plasticity: emerging concepts in cognitive reserve', *Trends in Cognitive Sciences*, 17(10), pp. 502–509. doi: 10.1016/j.tics.2013.08.012.Efficiency.

Basu, A., Krady, J. K. and Levison, S. (2004) 'Interleukin-1 : A Master Regulator of Neuroinflammation', *Journal of Neuroscience Research*, 78, pp. 151–156. doi: 10.1002/jnr.20266.

Beard, R. S., Reynolds, J. J. and Bearden, S. E. (2011) 'Hyperhomocysteinemia increases permeability of the blood-brain barrier by NMDA receptor-dependent regulation of adherens and tight junctions', *Blood*, 118(7), pp. 2007–2014. doi: 10.1182/blood-2011-02-338269.

Beek, A. H. E. A. Van *et al.* (2008) 'Cerebral autoregulation : an overview of current concepts and methodology with special focus on the elderly', *Journal of Cerebral Blood Flow {\&} Metabolism*, 28, pp. 1071–1085. doi: 10.1038/jcbfm.2008.13.

Belizário, J., Vieira-cordeiro, L. and Enns, S. (2015) 'Necroptotic Cell Death Signaling and Execution Pathway : Lessons from Knockout Mice', *Mediators of Inflammation*, 2015, p. 128076. doi: 10.1155/2015/128076.

van den Berg, E. *et al.* (2009) 'Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity : A systematic comparison of their impact

on cognition', *Biochimica et Biophysica Acta*, 1792(5), pp. 470–481. doi: 10.1016/j.bbadis.2008.09.004.

Bergsbaken, T., Fink, S. L. and Cookson, B. T. (2010) 'Pyroptosis: host cell death and inflammation', *Nature Reviews Microbiology*, 7(2), pp. 99–109. doi: 10.1038/nrmicro2070.Pyroptosis.

Blackburn, D. J. *et al.* (2013) 'Cognitive screening in the acute stroke setting', *Age and Ageing*, 42, pp. 113–116. doi: 10.1093/ageing/afs116.

Borrione, P. and Fossati, C. (2017) 'Hyperhomocysteinemia and Its Role in Cognitive Impairment and Alzheimer ' s Disease : Recent Updates from the Literature', *Endocrinology and Metabolism*, 1(1), p. 1.

Broughton, B. R. S., Reutens, D. C. and Sobey, C. G. (2009) 'Apoptotic Mechanisms After Cerebral Ischemia', *Stroke*, 40, pp. e331--e339. doi: 10.1161/STROKEAHA.108.531632.

Cacciapuoti, F. (2018) 'Poor re-Methylation of Homocysteine and Trans-Methylation of Methionine: Cause and Effect of Hyper-Homocysteinemia : Which Role for Folic Acid and Vitamins B- 6-12 Supplementation ?', *Annals of Clinical and Experimental Metabolism*, 3(1), p. 1026.

Cajavilca, C. E., Gadhia, R. R. and Roman, G. C. (2019) 'MTHFR Gene Mutations Correlate with White Matter Disease Burden and Predict Cerebrovascular Disease and Dementia', *Brain Sciences*, 9(9), p. 211. doi: 10.3390/brainsci9090211.

Camerino, I. *et al.* (2021) 'White matter hyperintensities at critical crossroads for executive function and verbal abilities in small vessel disease', *Human Brain Mapping*, 42(4), pp. 993–1002. doi: 10.1002/hbm.25273.

Chamorro, Á. *et al.* (2012) 'The immunology of acute stroke', *Nature Reviews Neurology*, 8(7), pp. 401–410. doi: 10.1038/nrneurol.2012.98.

Chen, G. Y. and Nunez, G. (2010) 'Sterile inflammation : sensing and

reacting to damage', *Nature Reviews Immunology*, 10(12), pp. 826–837. doi: 10.1038/nri2873.Sterile.

Chen, S. *et al.* (2017) 'Homocysteine exaggerates microglia activation and neuroinflammation through microglia localized STAT3 overactivation following ischemic stroke', *Journal of Neuroinflammation*, 17, p. 187. doi: 10.1186/s12974-017-0963-x.

Chiti, G. and Pantoni, L. (2014) 'Use of Montreal Cognitive Assessment in Patients With Stroke', *Stroke*, 45, pp. 3135–3140. doi: 10.1161/STROKEAHA.114.004590.

Lo Coco, D., Lopez, G. and Corrao, S. (2016) 'Cognitive impairment and stroke in elderly patients', *Vascular Health and Risk Management*, 12, pp. 105–116. doi: https://doi.org/10.2147/VHRM.S75306.

Crichton, S. L. *et al.* (2016) 'Patient outcomes up to 15 years after stroke: survival, disability, quality of life, cognition and mental health', *Journal of Neurology, Neurosurgery, and Psychiatry*, 87, pp. 1091–1098. doi: 10.1136/jnnp-2016-313361.

Cumming, T. B. *et al.* (2013) 'Montreal Cognitive Assessment and Mini – Mental State Examination are both valid cognitive tools in stroke', *Acta Neurologica Scandiavica*, 128, pp. 122–129. doi: 10.1111/ane.12084.

Cumming, T. B., Bernhardt, J. and Linden, T. (2011) 'The Montreal Cognitive Assessment Short Cognitive Evaluation in a Large Stroke Trial', *Stroke*, 42, pp. 2642–2644. doi: 10.1161/STROKEAHA.111.619486.

Cumming, T. B., Marshall, R. S. and Lazar, R. M. (2013) 'Stroke , cognitive deficits , and rehabilitation : still an incomplete picture', *International Journal of Stroke*, 8, pp. 38–45. doi: 10.1111/j.1747-4949.2012.00972.x.

D'Orsi, B., Mateyka, J. and Prehn, J. H. M. (2017) 'Control of mitochondrial physiology and cell death by the Bcl-2 family proteins Bax and Bok', *Neurochemistry International*, 109, pp. 162–170. doi:

10.1016/j.neuint.2017.03.010.

Dabrowski, J. *et al.* (2019) 'Brain Functional Reserve in the Context of Neuroplasticity after Stroke', *Neural Plasticity*, 2019, p. 9708905. Available at: https://doi.org/10.1155/2019/9708905.

Dacosta-Aguayo, R. *et al.* (2014) 'Structural Integrity of the Contralesional Hemisphere Predicts Cognitive Impairment in Ischemic Stroke at Three Months', *PLoS ONE*, 9(1), p. e86119. doi: 10.1371/journal.pone.0086119.

Dahlan, M. S. (2013) *Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan*. 3th edn. Jakarta: Salemba Medika.

Danovska, M. *et al.* (2012) 'Post-stroke cognitive impairment - phenomenology and prognostic', *Journal of IMAB*, 18, pp. 290–297. doi: 10.5272/jimab.2012183.290.

Declercq, W., Berghe, T. Vanden and Vandenabeele, P. (2009) 'Minireview RIP Kinases at the Crossroads of Cell Death and Survival', *Cell*, 138(2), pp. 229–232. doi: 10.1016/j.cell.2009.07.006.

Ding, R., Lin, S. and Chen, D. (2012) 'The association of Cystathionine $β$ Synthase (CBS) T833C polymorphism and the risk of stroke : A meta-analysis', *Journal of the Neurological Sciences*, 312(1–2), pp. 26–30. doi: 10.1016/j.jns.2011.08.029.

Dong, Y. *et al.* (2013) 'Cognitive screening improves the predictive value of stroke severity scores for functional outcome 3 – 6 months after mild stroke and transient ischaemic attack: an observational study', *BMJ Open*, 3, p. e003105. doi: 10.1136/bmjopen-2013-003105.

Dufouil, C. and Alpe, A. (2003) 'Homocysteine, White Matter Hyperintensities, and Cognition in Healthy Elderly People', *Annals of Neurology*, 53, pp. 214–221. doi: 10.1002/ana.10440.

Einstad, M. S. *et al.* (2021) 'Associations between post-stroke motor and cognitive function: a cross-sectional study', *BMC Geriatrics*, 21, p. 103. doi: 10.1186/s12877-021-02055-7.

Elhawary, N. A. *et al.* (2013) ‘The MTHFR 677T Allele May Influence the Severity and Biochemical Risk Factors of Alzheimer ’ s Disease in an Egyptian Population’, *Disease Markers*, 35(5), pp. 439–446.

Erta, M., Quintana, A. and Hidalgo, J. (2012) ‘Interleukin-6 , a Major Cytokine in the Central Nervous System’, *International Journal of Biological Sciences*, 8(9), pp. 1254–1266. doi: 10.7150/ijbs.4679.

Fallon, U. B. *et al.* (2001) ‘Homocysteine and ischaemic stroke in men : the Caerphilly study’, *Journal of Epidemiology and Community Health*, 55, pp. 91–96.

Fann, D. Y. *et al.* (2013) ‘Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke’, *Cell Death and Disease*, 4, p. e790. doi: 10.1038/cddis.2013.326.

Faraci, F. M. and Lentz, S. R. (2004) ‘Hyperhomocysteinemia, Oxidative Stress, and Cerebral Vascular Dysfunction’, *Stroke*, 35, pp. 345–347. doi: 10.1161/01.STR.0000115161.10646.67.

Farrall, A. J. and Wardlaw, J. M. (2009) ‘Blood – brain barrier : Ageing and microvascular disease – systematic review and meta-analysis’, *Neurobiology of Aging*, 30, pp. 337–352. doi: 10.1016/j.neurobiolaging.2007.07.015.

Fefelova, E. V *et al.* (2015) ‘Lymphocyte Subpopulations and Cytokine Levels in Experimental Hyperhomocysteinemia’, *Bulletin of Experimental Biology and Medicine*, 159(3), pp. 358–360. doi: 10.1007/s10517-015-2962-1.

Fokkema, M. R. H., van Doormaal, J. J. and Kema, I. (2003) ‘Fasting vs Nonfasting Plasma Homocysteine Concentrations for Diagnosis of Hyperhomocysteinemia’, *Clinical Chemistry*, 49(5), pp. 818–821. doi: 10.1373/49.5.818.

Ford, A. H. *et al.* (2012) ‘Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism and cognitive impairment: the health in men study’, *Molecular Psychiatry*, 17, pp. 559–566.

Fotuhi, M., Medicine, J. H. and Whitehouse, P. J. (2009) ‘Changing perspectives regarding late-life dementia’, *Nature Reviews Neurology*, 5, pp. 1–10. doi: 10.1038/nrneurol.2009.175.

Frosst, P. *et al.* (1995) ‘A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase’, *Nature Genetics*, 10, pp. 111–113.

Fulda, S. (2013) ‘Alternative Cell Death Pathways and Cell Metabolism’, *International Journal of Cell Biology*, 2013, p. 463637.

Gajurel, B. P. *et al.* (2014) ‘The National Institute of Health Stroke Scale Score and Outcome in Acute Ischemic Stroke’, *Journal of Institute of Medicine*, 36(3), pp. 9–13.

Galluzzi, L., Kroemer, G. and Villejuif, F.- (2008) ‘Necroptosis : A Specialized Pathway of Programmed Necrosis’, *Cell*, 135(7), pp. 1161–1163. doi: 10.1016/j.cell.2008.12.004.

Ganguli, M. *et al.* (2014) ‘Vascular risk factors and cognitive decline in a population sample’, *Alzheimer Disease and Associated Disorders*, 28(1), pp. 9–15. doi: 10.1097/WAD.0000000000000004.VASCULAR.

Ganguly, P. and Alam, S. F. (2015) ‘Role of homocysteine in the development of cardiovascular disease’, *Nutrition Journal*, 14, p. 6. Available at: http://www.nutritionj.com/content/14/1/6.

Gao, Y. *et al.* (2015) ‘Homocysteine Level Is Associated with White Matter Hyperintensity Locations in Patients with Acute Ischemic Stroke’, *PLoS ONE*, 10(12), p. e0144431. doi: 10.1371/journal.pone.0144431.

Gong, X. *et al.* (2013) ‘Prognostic Value of Inflammatory Mediators in 1-Year Outcome of Acute Ischemic Stroke with Middle Cerebral Artery Stenosis’, *Mediators of Inflammation*, 2013, p. 850714.

Gorelick, P. B. *et al.* (2011) ‘Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American

Stroke Association', *Stroke*, 42(9), pp. 2672–2713. doi: 10.1161/STR.0b013e3182299496.Vascular.

Gorelick, P. B., Counts, S. E. and Nyenhuis, D. (2016) 'Vascular cognitive impairment and dementia', *BBA - Molecular Basis of Disease*, 1862, pp. 860–868. doi: 10.1016/j.bbadis.2015.12.015.

Gorgone, G. *et al.* (2009) 'Hyperhomocysteinemia , intima-media thickness and C677T MTHFR gene polymorphism : A correlation study in patients with cognitive impairment', *Atherosclerosis*, 206, pp. 309–313. doi: 10.1016/j.atherosclerosis.2009.02.028.

Gottesman, R. F. and Hillis, A. E. (2010) 'Predictors and assessment of cognitive dysfunction resulting from ischaemic stroke', *Lancet Neurology*, 9(9), pp. 895–905. doi: 10.1016/S1474-4422(10)70164-2.Predictors.

Guo, S. *et al.* (2008) 'Neuroprotection via matrix-trophic coupling between cerebral endothelial cells and neurons', *Proceedings of the National Academy of Sciences*, 105(21), pp. 7582–7587.

Guthikonda, S. and Haynes, W. G. (2006) 'Homocysteine: Role and implications in atherosclerosis', *Current Atherosclerosis Reports*, 8(2), pp. 100–106. doi: 10.1007/s11883-006-0046-4.

Guttormsen, A. B. *et al.* (1993) 'Kinetics of Plasma Homocysteine in Healthy Subjects after Peroral Homocysteine Loading', *Clinical Chemistry*, 39(7), pp. 1390–1397.

Hainsworth, A. H. *et al.* (2016) 'Homocysteine, hyperhomocysteinemia and vascular contributions to cognitive impairment and dementia (VCID)', *Biochimica et Biophysica Acta*, 1862, pp. 1008–1017.

Halevi, D. R. *et al.* (2019) 'Cognitive deficits in acute mild ischemic stroke and TIA and effects of rt-PA', *Annals of Clinical and Translational Neurology*, 6(3), pp. 466–474. doi: 10.1002/acn3.719.

Handy, D. E., Zhang, Y. and Loscalzo, J. (2005) 'Homocysteine Down-regulates Cellular Glutathione Peroxidase (GPx1) by Decreasing Translation', *The Journal of Biological Chemistry*, 280(16), pp.

15518–15525. doi: 10.1074/jbc.M501452200.

Hassan, A. *et al.* (2004) 'Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction', *Brain*, 127, pp. 212–219.

Hsuchou, H. *et al.* (2012) 'C-Reactive Protein Increases BBB Permeability: Implications for Obesity and Neuroinflammation', *Cellular Physiology and Biochemistry*, 30(5), pp. 1109–1119.

Huang, X. *et al.* (2015) 'Autophagy in cerebral ischemia and the effects of traditional Chinese medicine', *Journal of Integrative Medicine*, 13(5), pp. 289–296. doi: 10.1016/S2095-4964(15)60187-X.

Hugo, J. and Ganguli, M. (2014) 'Dementia and Cognitive Impairment: Epidemiology, Diagnosis, and Treatment', 30(3), pp. 421–442. doi: 10.1016/j.cger.2014.04.001.Dementia.

Irizarry, M. C. *et al.* (2005) 'Association of homocysteine with plasma amyloid $_{L}^{N}$ protein in aging and neurodegenerative disease', *Neurology*, 65, pp. 1402–1408.

Jaillard, A. *et al.* (2009) 'Hidden Dysfunctioning in Subacute Stroke', *Stroke*, 40(7), pp. 2473–2479. doi: 10.1161/STROKEAHA.108.541144.

Jamil, K. (2014) 'Clinical Implications of MTHFR Gene Polymorphism in Various Diseases', *Biology and Medicine*, 6, p. e107. doi: 10.4172/0974-8369.S3-e101.

Jellinger, K. A. (2013) 'Pathology and pathogenesis of vascular cognitive impairment - a critical update', *Frontiers in Aging Neuroscience*, 5, p. 17. doi: 10.3389/fnagi.2013.00017.

Jiang, B. *et al.* (2014) 'Effects of differences in serum total homocysteine , folate , and vitamin B 12 on cognitive impairment in stroke patients', *BMC Neurology*, 14, p. 217.

Kalaria, R. N., Akinyemi, R. and Ihara, M. (2016) 'Stroke injury, cognitive impairment and vascular dementia', *Biochimica et Biophysica Acta - Molecular Basis of Disease*, 1862(5), pp. 915–925. doi:

10.1016/j.bbadis.2016.01.015.

Kamat, P. K. *et al.* (2015) 'Homocysteine Induced Cerebrovascular Dysfunction: A Link to Alzheimer's Disease Etiology', *The Open Neurology Journal*, 9, pp. 9–14.

Kamath, A. F. *et al.* (2006) 'Brief report Elevated levels of homocysteine compromise blood-brain barrier integrity in mice', *Blood*, 107(2), pp. 591–594. doi: 10.1182/blood-2005-06-2506.Supported.

Katkam, R. V, Ghodake, S. R. and Suryakar, A. N. (2017) 'Homocysteine-Induced Neurotoxicity and Oxidative Stress in Neuropsychiatric Disorders', *IOSR Journal of Biotechnology and Biochemistry*, 3(4), pp. 20–27. doi: 10.9790/264X-03042027.

Kauranen, T. *et al.* (2014) 'The cognitive burden of stroke emerges even with an intact NIH Stroke Scale Score : a cohort study', *Journal of Neurology, Neurosurgery, and Psychiatry*, 85, pp. 295–299. doi: 10.1136/jnnp-2013-305585.

Kazama, K. *et al.* (2004) 'Angiotensin II Impairs Neurovascular Coupling in Neocortex Through NADPH Oxidase – Derived Radicals', *Circulation Research*, 95, pp. 1019–1026. doi: 10.1161/01.RES.0000148637.85595.c5.

Keung, W., Lai, C. and Kan, M. Y. (2015) 'Homocysteine-Induced Endothelial Dysfunction', *Annals of Nutrition and Metabolism*, 67, pp. 1–12. doi: 10.1159/000437098.

Khedr, E. M. *et al.* (2009) 'Cognitive impairment after cerebrovascular stroke : Relationship to vascular risk factors', *Neuropsychiatric Disease and Treatment*, 5, pp. 103–116.

Kidwell, C. S. *et al.* (2001) 'Trends in Acute Ischemic Stroke Trials Through the 20th Century', *Stroke*, 32, pp. 1349–1359.

Kilinc, M. *et al.* (2010) 'Neurobiology of Disease Lysosomal rupture , necroapoptotic interactions and potential crosstalk between cysteine proteases in neurons shortly after focal ischemia', *Neurobiology of Disease*, 40(1), pp. 293–302. doi:

10.1016/j.nbd.2010.06.003.

Kim, J. Y. *et al.* (2016) ‘Inflammation after Ischemic Stroke : The Role of Leukocytes and Glial Cells’, *Experimental Neurobiology*, 25(5), pp. 241–251.

Kluwe-Schiavon, B. *et al.* (2013) ‘Rehabilitation of executive functions: Implications and strategies’, *Avances en Psicología Latinoamericana*, 31(1), pp. 110–120.

Knopman, D. S. *et al.* (2009) ‘Association of Prior Stroke with Cognitive Function and Cognitive Impairment: A Population-based Study’, *Archives of Neurology*, 66(5), pp. 614–619. doi: 10.1001/archneurol.2009.30.Association.

Knopman, D. S. and Petersen, R. C. (2014) ‘Mild Cognitive Impairment and Mild Dementia: A Clinical Perspective’, *mayo clinic proceedings*, 89(10), pp. 1452–1459. doi: 10.1016/j.mayocp.2014.06.019.Mild.

Kruman, I. I. *et al.* (2000) ‘Homocysteine Elicits a DNA Damage Response in Neurons That Promotes Apoptosis and Hypersensitivity to Excitotoxicity’, *The Journal of Neuroscience*, 20(18), pp. 6920–6926.

Kruman, I. I. *et al.* (2002) ‘Folic Acid Deficiency and Homocysteine Impair DNA Repair in Hippocampal Neurons and Sensitize Them to Amyloid Toxicity in Experimental Models of Alzheimer ’ s Disease’, *The Journal of Neuroscience*, 22(5), pp. 1752–1762.

Laks, J. *et al.* (2005) ‘Prevalence of cognitive and functional impairment in community-dwelling elderly. Importance of evaluating activities of daily living’, *Arquivos de Neuro-Psiquiatria*, 63(2-A), pp. 207–212.

Lam, J. C. M., Sharma, S. K. and Lam, B. (2010) ‘Obstructive sleep apnoea: definitions, epidemiology {\&} natural history.’, *The Indian journal of medical research*, 131(February), pp. 165–170.

Lamers, Y. *et al.* (2011) ‘Moderate Vitamin B-6 Restriction Does Not Alter Postprandial Methionine Cycle Rates of Remethylation,

Transmethylation, and Total Transsulfuration but Increases the Fractional Synthesis Rate of Cystathionine in Healthy Young Men and Women', *The Journal of Nutrition*, 141(5), pp. 835–842. doi: 10.3945/jn.110.134197.

Leclerc, D., Sibani, S. and Rozen, R. (2013) 'Molecular Biology of Methylenetetrahydrofolate Reductase (MTHFR) and Overview of Mutations/Polymorphisms', in *Madame Curie Bioscience Database*. Austin (TX): Landes Bioscience. Available at: https://www.ncbi.nlm.nih.gov/books/NBK6561/.

Lees, R. *et al.* (2012) 'Cognitive and Mood Assessment in Stroke Research Focused Review of Contemporary Studies', *Stroke*, 43, pp. 1678–1680. doi: 10.1161/STROKEAHA.112.653303.

Lehotsky, J. *et al.* (2016) 'Role of Homocysteine in the Ischemic Stroke and Development of Ischemic Tolerance', *Frontiers in Neuroscience*, 10, p. 538. doi: 10.3389/fnins.2016.00538.

Lentz, S. R. (2001) 'Does Homocysteine Promote Atherosclerosis?', *Arteriosclerosis, Thrombosis, and Vasscular Biology*, 21, pp. 1385–1386. Available at: http://www.atvbaha.org.

Lesniak, M. *et al.* (2008) 'Frequency and Prognostic Value of Cognitive Disorders in Stroke Patients', *Dementia and Geriatric Cognitive Disorders*, 26, pp. 356–363. doi: 10.1159/000162262.

Lestari, S. *et al.* (2017) 'Comparison between mini mental state examination (MMSE) and Montreal cognitive assessment Indonesian version (MoCA-Ina) as an early detection of cognitive impairments in post-stroke patients', *Journal of Physics: Conference Series*, 884, p. 12153.

Levine, D. A. *et al.* (2018) 'Risk Factors for Post-Stroke Cognitive Decline: the REGARDS study', *Stroke*, 49(4), pp. 987–994. doi: 10.1161/STROKEAHA.117.018529.Risk.

Li, A. *et al.* (2017) 'A possible synergistic effect of MTHFR C677T polymorphism on homocysteine level variations increased risk for

ischemic stroke', *Medicine*, 96(51), p. e9300. doi: 10.1097/MD.0000000000009300.

Li, T. *et al.* (2015) 'Serum Homocysteine Concentration Is Significantly Associated with Inflammatory / Immune Factors', *PLoS ONE*, 10(9), p. e0138099. doi: 10.1371/journal.pone.0138099.

Liew, S.-C. and Gupta, E. Das (2015) 'Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: Epidemiology, metabolism and the associated diseases', *European Journal of Medical Genetics*, 58(1), pp. 1–10. doi: 10.1016/j.ejmg.2014.10.004.

Lim, K. *et al.* (2018) 'Correlation Between Montreal Cognitive Assessment and Functional Outcome in Subacute Stroke Patients With Cognitive Dysfunction', *Annals of Rehabilitation Medicine*, 42(1), pp. 26–34.

Lin, N. *et al.* (2014) 'Homocysteine induces cytotoxicity and proliferation inhibition in neural stem cells via DNA methylation in vitro', *FEBS Journal*, 281, pp. 2088–2096. doi: 10.1111/febs.12764.

Lipton, S. A. *et al.* (1997) 'Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor', *Proceedings of the National Academy of Sciences of the United States of America*, 94, pp. 5923–5928.

Liu, R. *et al.* (2017) 'Role of neuroinflammation in ischemic stroke', *Neuroimmunology and Neuroinflammation*, 4, pp. 158–166. doi: 10.20517/2347-8659.2017.09.

Loscalzo, J. (1996) 'The Oxidant Stress of Hyperhomocyst(e)inemia', *Journal of Clinical Investigation*, 98(1), pp. 5–7.

Lu, H. *et al.* (2013) 'DNA methylation, a hand behind neurodegenerative diseases', *Frontiers in Aging Neuroscience*, 5, p. 85. doi: 10.3389/fnagi.2013.00085.

Lu, S. *et al.* (2019) 'Prevalence of hypertension, diabetes, and dyslipidemia, and their additive effects on myocardial infarction and

stroke: a cross-sectional study in Nanjing, China', *Annals of Translational Medicine*, 7(18), p. 436. doi: 10.21037/atm.2019.09.04.

Marchesi, C., Paradis, P. and Schiffrin, E. L. (2008) 'Role of the renin – angiotensin system in vascular inflammation', *Trends in Pharmacological Sciences*, 29(7), pp. 367–374. doi: 10.1016/j.tips.2008.05.003.

Marini, N. J. *et al.* (2008) 'The prevalence of folate-remedial MTHFR enzyme variants in humans', *Proceedings of the National Academy of Sciences*, 105(23), pp. 8055–8060.

Marshall, G. A. *et al.* (2011) 'Executive function and instrumental activities of daily living in MCI and AD', *Alzheimer's {\&} Dementia*, 7(3), pp. 300–308. doi: 10.1016/j.jalz.2010.04.005.

Matsui, T., Arai, H. and Yuzuriha, T. (2001) 'Elevated Plasma Homocysteine Levels and Risk of Silent Brain Infarction in Elderly People', pp. 1116–1119.

McAuley, E. *et al.* (2016) 'Riboflavin status, MTHFR genotype and blood pressure: current evidence and implications for personalised nutrition', *Proceedings of the Nutrition Society*, 75, pp. 405–414. doi: 10.1017/S0029665116000197.

McCoy, M. K. and Tansey, M. G. (2008) 'TNF signaling inhibition in the CNS : implications for normal brain function and neurodegenerative disease', *Jounal of Neuroinflammation*, 5, p. 45. doi: 10.1186/1742-2094-5-45.

McKenzie, B. A. *et al.* (2018) 'Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis', *Proceedings of the National Academy of Sciences*, 115(26), pp. 6065–6074. doi: 10.1073/pnas.1722041115.

McNulty, H. *et al.* (2006) 'Riboflavin Lowers Homocysteine in Individuals Homozygous for the MTHFR 677CT Polymorphism', *Circulation*, 113, pp. 74–80. doi: 10.1161/CIRCULATIONAHA.105.580332.

Mehta, S. L. and Vemuganti, R. (2014) ‘Mechanisms of Stroke Induced Neuronal Death: Multiple Terapeutic Opportunities’, *Advances in Animal and Veterinary Sciences*, 2(8), pp. 438–446.

Meng, S. *et al.* (2013) ‘Homocysteine induces inflammatory transcriptional signaling in monocytes’, *Frontiers in Bioscience*, 18, pp. 685–695.

Mijajlovic, M. D. *et al.* (2017) ‘Post-stroke dementia – a comprehensive review’, *BMC Medicine*, 15(1), p. 11. doi: 10.1186/s12916-017-0779-7.

Miller, A. L. (2003) ‘The Methionine-Homocysteine Cycle and Its Effects on Cognitive Diseases’, *Alternative Medicine Review*, 8(1), pp. 7–19. doi: 10.1007/978-3-322-81541-5.

Mizrahi, E. H. *et al.* (2005) ‘Plasma Homocysteine Level and Functional Outcome of Patients With Ischemic Stroke’, *Archives of Physical Medicine and Rehabilitation*, 86, pp. 60–63. doi: 10.1016/j.apmr.2004.01.031.

Mok, V. C. T. *et al.* (2004) ‘Cognitive impairment and functional outcome after stroke associated with small vessel disease’, *Journal of Neurology, Neurosurgery, and Psychiatry*, 75, pp. 560–566. doi: 10.1136/jnnp.2003.015107.

Moll, S. and Varga, E. A. (2015) ‘Homocysteine and MTHFR Mutations’, *Circulation*, 132, pp. e6--e9. doi: 10.1161/CIRCULATIONAHA.114.013311.

Moorthy, D. *et al.* (2012) ‘Status of Vitamins B-12 and B-6 but Not of Folate, Homocysteine, and the Methylenetetrahydrofolate Reductase C677T Polymorphism Are Associated with Impaired Cognition and Depression in Adults1 – 3’, *The Journal of Nutrition*, 142(8), pp. 1554–1560. doi: 10.3945/jn.112.161828.

Moskowitz, M. A., Lo, E. H. and Iadecola, C. (2010) ‘The Science of Stroke : Mechanisms in Search of Treatments’, *Neuron*, 67(2), pp. 181–198. doi: 10.1016/j.neuron.2010.07.002.

Nam, K.-W. *et al.* (2019) ‘Serum homocysteine level is related to cerebral

small vessel disease in a healthy population', *Neurology*, 92(4), pp. e317--e325.

Niizuma, K. *et al.* (2010) 'Mitochondrial and apoptotic neuronal death signaling pathways in cerebral ischemia', *BBA - Molecular Basis of Disease*, 1802(1), pp. 92–99. doi: 10.1016/j.bbadis.2009.09.002.

Ntaios, G. *et al.* (2015) 'Predicting Functional Outcome and Symptomatic Intracranial Hemorrhage in Patients With Acute Ischemic Stroke', *Stroke*, 46, pp. 899–908. doi: 10.1161/STROKEAHA.114.003665.

Nys, G. M. S. *et al.* (2005) 'Domain-specific cognitive recovery after first-ever stroke : A follow-up study of 111 cases', *Journal of the International Neuropsychological Society*, 11, pp. 795–806.

Nys, G. M. S. *et al.* (2007) 'Cognitive Disorders in Acute Stroke : Prevalence and Clinical Determinants', *Cerebrovascular Diseases*, 23, pp. 408–416. doi: 10.1159/000101464.

Obaid, M. *et al.* (2020) 'Long-Term Outcomes in Stroke Patients with Cognitive Impairment: A Population-Based Study', *Geriatrics*, 5(2), p. 32. doi: 10.3390/geriatrics5020032.

Obeid, R. and Herrmann, W. (2006) 'Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia', *FEBS Letters*, 580, pp. 2994–3005. doi: 10.1016/j.febslet.2006.04.088.

Oikonomidi, A. *et al.* (2016) 'Homocysteine metabolism is associated with cerebrospinal fluid levels of soluble amyloid precursor protein and amyloid beta', *Journal of Neurochemistry*, 139, pp. 324–332. doi: 10.1111/jnc.13766.

Olivera, S. *et al.* (2011) 'Homocysteine: Neurotoxicity and Mechanisms of Induced Hyperexcitability', *Serbian Journal of Experimental and Clinical Research*, 12(1), pp. 3–9.

Olmos, G. and Lladó, J. (2014) 'Tumor Necrosis Factor Alpha : A Link between Neuroinflammation and Excitotoxicity', *Mediators of Inflammation*, 2014, p. 861231.

Paker, N. *et al.* (2010) ‘Impact of Cognitive Impairment on Functional Outcome in Stroke’, *Stroke Research and treatment*, 2010, p. 652612. doi: 10.4061/2010/652612.

Parzych, K. R. and Klionsky, D. J. (2014) ‘An Overview of Autophagy: Morphology, Mechanism, and Regulation’, *Antioxidants adn Redox Signaling*, 20(3), pp. 460–473. doi: 10.1089/ars.2013.5371.

Pençe, H. H. *et al.* (2019) ‘MTHFR C677T and A1298C Gene Polymorphisms in Human Kidney Cancer Tissues’, *Istanbul Medical Journal*, 20(5), pp. 408–412. doi: 10.4274/imj.galenos.2019.88709.

Pendlebury, S. T. *et al.* (2010) ‘Underestimation of Cognitive Impairment by Mini-Mental State Examination Versus the Montreal Cognitive Assessment in Patients With Transient Ischemic Attack and Stroke: A Population-Based Study’, *Stroke*, 41, pp. 1290–1293. doi: 10.1161/STROKEAHA.110.579888.

Pendlebury, S. T. and Rothwell, P. M. (2009) ‘Prevalence , incidence , and factors associated with pre-stroke and post-stroke dementia : a systematic review and meta-analysis’, *The Lancet Neurology*, 8, pp. 1006–1018. doi: 10.1016/S1474-4422(09)70236-4.

Perna, A. F., Ingrosso, D. and Santo, N. G. De (2003) ‘Homocysteine and oxidative stress’, *Amino Acids*, 25, pp. 409–417. doi: 10.1007/s00726-003-0026-8.

Petras, M. *et al.* (2014) ‘Hyperhomocysteinemia as a risk factor for the neuronal system disorders’, *Journal of Physiology and Pharmacology*, 65(1), pp. 15–23.

Poddar, R. *et al.* (2017) ‘Role of AMPA receptors in homocysteine-NMDAR induced crosstalk between ERK and p38 MAP kinase’, *Journal of Neurochemistry*, 142(4), pp. 560–573. doi: 10.1111/jnc.14078.Role.

Poddar, R. and Paul, S. (2009) ‘Homocysteine-NMDA receptor mediated activation of extracellular-signal regulated kinase leads to neuronal cell death’, *Journal of Neurochemistry*, 110(3), pp. 1095–1106. doi:

10.1111/j.1471-4159.2009.06207.x.Homocysteine-NMDA.

Povroznik, J. M. *et al.* (2018) 'Executive (dys)Function after Stroke: Special Considerations for Behavioral Pharmacology', *Behavioural Pharmacology*, 29(7), pp. 638–653. doi: 10.1097/FBP.0000000000000432.

Pramukarso, D. T. *et al.* (2015) 'Association between methylenetetrahydrofolate reductase (MTHFR) polymorphism and carotid intima medial thickness progression in post ischaemic stroke patient', *Annals of Translational Medicine*, 3(21), p. 324. doi: 10.3978/j.issn.2305-5839.2015.12.22.

Prodjohardjono, A. *et al.* (2020) 'Higher level of acute serum VEGF and larger infarct volume are more frequently associated with post-stroke cognitive impairment', *PLoS ONE*, 15(10), p. e0239370. doi: 10.1371/journal.pone.0239370.

Puig, B., Brenna, S. and Magnus, T. (2018) 'Molecular Communication of a Dying Neuron in Stroke', *International Journal of Molecular Sciences*, 19(9), p. E2834.

Rabinovici, G. D., Stephens, M. L. and Possin, K. L. (2015) 'Executive Dysfunction', *Continuum (Minneap Minn)*, 21(3 Behavioral Neurology and Neuropsychiatry), pp. 646–659. doi: 10.1212/01.CON.0000466658.05156.54.

Rajagopalan, P. *et al.* (2011) 'Homocysteine effects on brain volumes mapped in 732 elderly individuals', *Neuroreport*, 22(8), pp. 391–395. doi: 10.1097/WNR.0b013e328346bf85.Homocysteine.

Refsum, H. *et al.* (1998) 'Hyperhomocysteinemia in terms of steady-state kinetics', *European Journal of Pediatrics*, 157(Suppl 2), pp. S45--S49. doi: 10.1007/PL00014303.

Renjen, P. N., Gauba, C. and Chaudhari, D. (2015) 'Cognitive Impairment After Stroke', *Cureus*, 7(9), p. e335. doi: 10.7759/cureus.335.

Ritarwan, K. *et al.* (2020) 'The Correlation between Hematological Parameters and Transcranial Color Doppler (TCD) with Severity of

Acute Ischemic Stroke - A Cross-Sectional Study', *Systematic Reviews in Pharmacy*, 11(2), pp. 510–515. doi: 10.5530/srp.2020.2.78.

Rohde, D. *et al.* (2017) 'Secondary prevention and cognitive function after stroke: a study protocol for a 5-year follow-up of the ASPIRE-S cohort', *BMJ Open*, 7, p. e014819. doi: 10.1136/bmjopen-2016-014819.

Roman, G. C., Mancera-Paez, O. and Bernal, C. (2019) 'Epigenetic Factors in Late-Onset Alzheimer's Disease: MTHFR and CTH Gene Polymorphisms, Metabolic Transsulfuration and Methylation Pathways, and B Vitamins', *International Journal of Molecular Sciences*, 20, p. 319. doi: 10.3390/ijms20020319.

Rosenberg, N. *et al.* (2002) 'The Frequent 5,10-Methylenetetrahydrofolate Reductase C677T Polymorphism Is Associated with a Common Haplotype in Whites, Japanese, and Africans', *American Journal of Human Genetics*, 70, pp. 758–762.

Rowan, E. N. *et al.* (2007) 'Homocysteine and post-stroke cognitive decline', *Age and Ageing*, 36(3), pp. 339–343. doi: 10.1093/ageing/afm028.

Rubinsztein, D. C., Bento, C. F. and Deretic, V. (2015) 'Therapeutic targeting of autophagy in neurodegenerative and infectious diseases', *The Journal of Experimental Medicine*, 212(7), pp. 979–990. doi: 10.1084/jem.20150956.

Rutten-Jacobs, L. C. A. *et al.* (2016) 'Association of MTHFR C677T Genotype With Ischemic Stroke Is Confined to Cerebral Small Vessel Disease Subtype', *Stroke*, 47(3), pp. 646–651. doi: 10.1161/STROKEAHA.115.011545.

Sablot, D. *et al.* (2011) 'Predicting Acute Ischaemic Stroke Outcome Using Clinical and Temporal Thresholds', *ISRN Neurology*, 2011, p. 354642. doi: 10.5402/2011/354642.

Sachdev, P. S. *et al.* (2002) 'Relationship between plasma homocysteine

levels and brain atrophy in healthy elderly individuals', *Neurology*, 58, pp. 1539–1544.

Sachdev, P. S. *et al.* (2003) 'Homocysteine as a Risk Factor for Cognitive Impairment in Stroke Patients', *Dementia and Geriatric Cognitive Disorders*, 15, pp. 155–162.

Sachdev, P. S. *et al.* (2014) 'Classifying neurocognitive disorders: the DSM - 5 approach', *Nature Reviews Neurology*, 10, pp. 634–642. doi: 10.1038/nrneurol.2014.181.

Sachdev, P. S., Valenzuela, M. J. and Brodaty, H. (2003) 'Homocysteine as a risk factor for cognitive impairment in stroke patients', *Dementia and Geriatric Cognitive Disorders*, 15, pp. 155–162.

Sadiq, M. *et al.* (2014) 'Frequency of hyper-homocysteinaemia in ischaemic stroke patients of Karachi', *Journal of Pakistan Medical Association*, 64(9), pp. 1063–1066.

Sahathevan, R., Brodtmann, A. and Donnan, G. A. (2012) 'Dementia, stroke, and vascular risk factors ; a review', *International Journal of Stroke*, 7, pp. 61–73. doi: 10.1111/j.1747-4949.2011.00731.x.

Salomão, R. G. *et al.* (2018) 'Homocysteine, folate, hs-C-reactive protein, tumor necrosis factor alpha and inflammatory proteins: are these biomarkers related to nutritional status and cardiovascular risk in childhood-onset systemic lupus erythematosus?', *Pediatric Rheumatology*, 16(1), p. 4. doi: 10.1186/s12969-017-0220-y.

Sekerdag, E., Solaroglu, I. and Gursoy-Ozdemir, Y. (2018) 'Cell Death Mechanisms in Stroke and Novel Molecular and Cellular Treatment Options', *Current Neuropharmacology*, 16(9), pp. 1396–1415.

Sharma, R. *et al.* (2020) 'Early Post-stroke Cognition: In-hospital Predictors and the Association With Functional Outcome', *Frontiers in Neurology*, 11, p. 613607. doi: 10.3389/fneur.2020.613607.

Shatzman, S., Mahajan, S. and Sundararajan, S. (2016) 'Often Overlooked but Critical: Poststroke Cognitive Impairment in Right Hemispheric Ischemic Stroke', *Stroke*, 47(9), pp. e221--e223. doi:

10.1161/STROKEAHA.116.014280.

Sheng, R. *et al.* (2012) ‘Autophagy regulates endoplasmic reticulum stress in ischemic preconditioning’, *Autophagy*, 8(3), pp. 310–325. doi: 10.4161/auto.18673.

Shi, Z. *et al.* (2018) ‘Changes in total homocysteine levels after acute stroke and recurrence of stroke’, *Scientific Reports*, 8, p. 6993. doi: 10.1038/s41598-018-25398-5.

Shin, M. *et al.* (2020) ‘Effect of Cognitive Reserve on Risk of Cognitive impairment and Recovery After Stroke. The KOSCO Study’, *Stroke*, 51, pp. 99–107. doi: 10.1161/STROKEAHA.119.026829.

Sims, N. R. and Muyderman, H. (2010) ‘Mitochondria , oxidative metabolism and cell death in stroke’, *BBA - Molecular Basis of Disease*, 1802(1), pp. 80–91. doi: 10.1016/j.bbadis.2009.09.003.

Singh-Manoux, A. *et al.* (2014) ‘Interleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife’, *Neurology*, 83, pp. 486–493.

Škovierová, H. *et al.* (2015) ‘Effect of Homocysteine on Survival of Human Glial Cells’, *Physiological Research*, 64, pp. 747–754.

St-Hilaire, A. *et al.* (2016) ‘Normative data for phonemic and semantic verbal fluency test in the adult French – Quebec population and validation study in Alzheimer’s disease and depression’, *The Clinical Neuropsychologist*, 30(7), pp. 1126–1150. doi: 10.1080/13854046.2016.1195014.

Stern, Y. (2013) ‘Cognitive Reserve: Implications for Assessment and Intervention’, *Folia Phoniatrica et Logopaedica*, 65(2), pp. 49–54. doi: 10.1159/000353443.Cognitive.

Storch, K. J. *et al.* (1988) ‘Quantitative study in vivo of methionine cycle in humans using [methyZ-2H3]- and [I-13C] methionine’, *The American Journal of Physiology*, 255(3 Pt 1), pp. E322--31. doi: 10.1152/ajpendo.1988.255.3.E322.

Sudduth, T. L. *et al.* (2013) ‘Induction of hyperhomocysteinemia models

vascular dementia by induction of cerebral microhemorrhages and neuroinflammation', *Journal of Cerebral Blood Flow {\&} Metabolism*, 33(5), pp. 708–715. doi: 10.1038/jcbfm.2013.1.

Swardfager, W. *et al.* (2013) 'Interleukin-17 in post-stroke neurodegeneration', *Neuroscience and Biobehavioral Reviews*, 37(3), pp. 436–447.

Takeda, S., Rakugi, H. and Morishita, R. (2020) 'Roles of vascular risk factors in the pathogenesis of dementia', *Hypertension Research*, 43, pp. 162–167. doi: 10.1038/s41440-019-0357-9.

Tang, Y. *et al.* (2016) 'The critical roles of mitophagy in cerebral ischemia', *Protein {\&} Cell*, 7(10), pp. 699–713. doi: 10.1007/s13238-016-0307-0.

Tegene, E. *et al.* (2019) 'Prevalence and risk factors for atrial fibrillation and its anticoagulant requirement in adults aged ≥40 in Jimma Town, Southwest Ethiopia: A community based cross-sectional study', *IJC Heart {\&} Vasculature*, 22, pp. 199–204. doi: 10.1016/j.ijcha.2019.02.003.

Terasaki, Y. *et al.* (2014) 'Mechanisms of Neurovascular Dysfunction in Acute Ischemic Brain', *Current Medical Chemistry*, 21(18), pp. 2035–2042.

Toglia, J. *et al.* (2011) 'The Mini-Mental State Examination and Montreal Cognitive Assessment in Persons With Mild Subacute Stroke : Relationship to Functional Outcome', *Archives of Physical Medicine and Rehabilitation*, 92(5), pp. 792–798. doi: 10.1016/j.apmr.2010.12.034.

Vitvitsky, V. *et al.* (2003) 'Redox regulation of homocysteine-dependent glutathione synthesis', *Redox Report*, 8(1), pp. 57–63. doi: 10.1179/135100003125001260.

Wan, L. *et al.* (2018) 'Methylenetetrahydrofolate reductase and psychiatric diseases', *Translational Psychiatry*, 8, p. 242. doi: 10.1038/s41398-018-0276-6.

Wang, C. *et al.* (2014) ‘Elevated plasma homocysteine level is associated with ischemic stroke in Chinese hypertensive patients’, *European Journal of Internal Medicine*, 25(6), pp. 538–544. doi: 10.1016/j.ejim.2014.04.011.

Wang, G., Siow, Y. L. and Karmin, O. (2000) ‘Homocysteine stimulates nuclear factor jB activity and monocyte chemoattractant protein-1 expression in vascular smooth-muscle cells : a possible role for protein kinase C’, *Biochemical Journal*, 352, pp. 817–825.

Wang, W. *et al.* (2017) ‘No Association between Elevated Total Homocysteine Levels and Functional Outcome in Elderly Patients with Acute Cerebral Infarction’, *Frontiers in Aging Neuroscience*, 9, p. 70. doi: 10.3389/fnagi.2017.00070.

Weekman, E. M. *et al.* (2017) ‘Hyperhomocysteinemia-Induced Gene Expression Changes in the Cell Types of the Brain’, *American Society for Neurochemistry*, 9(6), p. 1759091417742296. doi: 10.1177/1759091417742296.

Wolburg, H. *et al.* (2009) ‘Brain endothelial cells and the glio-vascular complex’, *Cell and Tissue Research*, 335, pp. 75–96. doi: 10.1007/s00441-008-0658-9.

Wu, L. *et al.* (2014) ‘Inflammatory response and neuronal necrosis in rats with cerebral ischemia’, *Neural Regeneration Research*, 9(19), pp. 1753–1762. doi: 10.4103/1673-5374.143419.

Wu, X. *et al.* (2014) ‘Plasma homocysteine levels and genetic polymorphisms in folate metablism are associated with breast cancer risk in chinese women’, *Hereditary Cancer in Clinical Practice*, 12(1), p. 2. doi: 10.1186/1897-4287-12-2.

Xi, H. *et al.* (2016) ‘Caspase-1 Inflammasome Activation Mediates HomocysteineInduced Pyrop-Apoptosis in Endothelial Cells’, *Circulation Research*, 118(10), pp. 1525–1539. doi: 10.1161/CIRCRESAHA.116.308501.Caspase-1.

Yang, K. E. M. *et al.* (2014) ‘Methylenetetrahydrofolate reductase C677T

gene polymorphism and essential hypertension : A meta - analysis of 10,415 subjects', *Biomedical Reports*, 2, pp. 699–708. doi: 10.3892/br.2014.302.

Yuan, J. (2009) 'Neuroprotective strategies targeting apoptotic and necrotic cell death for stroke', *Apoptosis*, 14(4), pp. 469–477. doi: 10.1007/s10495-008-0304-8.Neuroprotective.

Yuan, J., Najafov, A. and Py, B. F. (2016) 'Roles of Caspases in Necrotic Cell Death', *Cell*, 167(7), pp. 1693–1704. doi: 10.1016/j.cell.2016.11.047.

Zhang, J.-W. *et al.* (2017) 'Hyperhomocysteinemia-induced autophagy and apoptosis with downregulation of hairy enhancer of split 1/5 in cortical neurons in mice', *International Journal of Immunopathology and Pharmacology*, 30(4), pp. 371–382. doi: 10.1177/0394632017740061.

Zhao, L. *et al.* (2018) 'Strategic infarct location for post-stroke cognitive impairment: A multivariate lesion-symptom mapping study', *Journal of Cerebral Blood Flow {\&} Metabolism*, 38(8), pp. 1299–1311. doi: 10.1177/0271678X17728162.

Zhao, Y. *et al.* (2016) 'Homocysteine Aggravates Cortical Neural Cell Injury through Neuronal Autophagy Overactivation following Rat Cerebral Ischemia-Reperfusion', *International Journal of Molecular Sciences*, 17, p. 1196. doi: 10.3390/ijms17081196.

Zhuo, J. *et al.* (2010) 'Diet-Induced Hyperhomocysteinemia Increases Amyloid-β Formation and Deposition in a Mouse Model of Alzheimer's Disease', *Current Alzheimer Research*, 7(2), pp. 140–149.

Zietemann, V. *et al.* (2018) 'Early MoCA predicts long-term cognitive and functional outcome and mortality after stroke', *Neurology*, 91, pp. e1838--e1850. doi: 10.1212/WNL.0000000000006506.

Zlokovic, B. V (2008) 'The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders', *Neuron*, 57(2), pp. 178–201. doi:

10.1016/j.neuron.2008.01.003.

Zou, C.-G. and Banerjee, R. (2005) ‘Homocysteine and Redox Signaling’, *Antioxidants adn Redox Signaling*, 7(5 {\&} 6), pp. 547–559.

Zulkifly, M. F. M. *et al.* (2016) ‘A Review of Risk Factors for Cognitive Impairment in Stroke Survivors’, *The Scientific World Journal*, 2016, p. 3456943.

Zuo, L. *et al.* (2016) ‘Screening for cognitive impairment with the Montreal Cognitive Assessment in Chinese patients with acute mild stroke and transient ischaemic attack : a validation study’, *BMJ Open*, 6, p. e011310. doi: 10.1136/bmjopen-2016-011310.

LAMPIRAN-LAMPIRAN

Lampiran 1. Surat Rekomendasi Persetujuan Etik dari Komisi Etik Penelitian

KEMENTERIAN RISET, TEKNOLOGI DAN PENDIDIKAN TINGGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari,.MMed.PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK
Nomor : 1077/UN4.6.4.5.31/ PP36/ 2019

Tanggal: 11 Nopember 2019

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH19090668	No Sponsor Protokol	
Peneliti Utama	**dr. Herpan Syafii Harahap, SpS**	Sponsor	
Judul Peneliti	Hubungan Antara Polimorfisme Gen Methylenetetrahydrofolate Reductase (MTHFR) C677T Dengan Gangguan Fungsi Kognitif Pasien Pasca Stroke Iskemik		
No Versi Protokol	**2**	Tanggal Versi	**1 Nopember 2019**
No Versi PSP	**2**	Tanggal Versi	**1 Nopember 2019**
Tempat Penelitian	**RS Universitas Hasanuddin Makassar, RSUD Provinsi NTB, RSUD Kota Mataram dan RSI Siti Hajar Mataram**		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku **11 Nopember 2019** sampai **11 Nopember 2020**	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:
- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2. Formulir Data Subjek Penelitian

DATA SUBJEK PENELITIAN

1. Identitas Pasien:

Nama : ……

Umur : …… tahun

Jenis Kelamin : Laki-laki / Perempuan *

Tingkat Pendidikan : ……

Lama Pendidikan : ……

Alamat : ……

No. Rekam Medik : ……

No. Telepon : ……

Tanggal Pemeriksaan : ……

Rumah Sakit : ……

2. Data Riwayat Stroke Iskemik:

Waktu dari awitan stroke iskemik : 2 – 4 minggu / 5 – 8 minggu / 9 – 12 minggu

Hemiparesis : kanan / kiri *

Hasil CT sken kepala saat diagnosis stroke iskemik (tanggal pemeriksaan) : ……
……

3. Pola Hidup (Life Style):

Merokok : ya / tidak *

Jika Ya, lama merokok : …… tahun

Berapa batang : …… /hari

4. Riwayat Penyakit:

- Hipertensi : Ya / Tidak *
  Jika Ya,
  - Terapi antihipertensi : Ya / Tidak *
    - Nama obat dan dosis yang diminum : …….
- Diabetes Melitus : Ya / Tidak *
  Jika Ya, nama obat dan dosis yang diminum : …….

5. **Data Antropometri Subjek:**

Tinggi Badan	: ……..	cm	Berat Badan	: ……	Kg
Lingkar Perut/pinggang	: ……..	cm	Lingkar panggul	: ……	cm

6. **Pemeriksaan Elektrokardiografi (EKG) :**
   - Fibrilasi atrium (AF) : Ya / Tidak *

7. **Keterangan Obat-obatan (nama, dosis, dan frekuensi pemberian) yang dikonsumsi saat ini:**

8. **Hasil Laboratorium :**
   - Kadar glukosa darah puasa : …….. mg/dL
   - Kadar glukosa darah 2 jam PP : ……. mg/dL
   - Kadar kolesterol total serum : ……. mg/dL
   - Kadar HDL serum : ……. mg/dL
   - Kadar LDL serum : ……. mg/dL
   - Kadar trigliserida serum : ……. mg/dL

9. **Hasil Pemeriksaan EKG (hasil ditempel) :**

Catatan :

*) Coret yang tidak perlu

Lampiran 3. Penjelasan Sebelum Penelitian

Peneliti adalah Mahasiswa Program S3 Fakultas Kedokteran Universitas Hasanuddin yang akan melakukan penelitian dengan judul **"Hubungan antara Polimorfisme Gen *Methylenetetrahydrofolate Reductase* (MTHFR) C677T dengan Gangguan Fungsi Kognitif Pasien Pasca Stroke Iskemik."**

Latar Belakang
Gangguan kognitif pasca stroke iskemik saat ini menjadi salah satu komplikasi dari stroke iskemik yang perlu mendapatkan perhatian penting. Satu dari 10 penderita stroke pertama kali akan mengalami gangguan kognitif dengan spektrum yang cukup luas, yaitu mulai dari gangguan kognitif ringan sampai dengan berat (demensia). Peningkatan kadar homosistein dalam darah merupakan salah satu faktor risiko untuk terjadinya gangguan kognitif pasca stroke iskemik. Salah satu faktor penting yang mendasari terjadinya peningkatan kadar homosistein dalam darah adalah adanya polimorfisme gen MTHFR C677T.

Tujuan penelitian
Penelitian ini bertujuan untuk membuktikan adanya hubungan yang bermakna antara polimorfisme gen *Methylenetetrahydrofolate Reductase* (MTHFR) C677T dengan gangguan fungsi kognitif pasca stroke iskemik.

Manfaat bagi partisipan
Dengan berpartisipasi dalam penelitian ini, Anda dapat mengetahui apakah Anda memiliki gen MTHFR normal (CC) atau memiliki polimorfisme gen, baik heterozigot (CT) maupun homozigot (TT), dan status fungsi kognitif anda setelah mengalami stroke iskemik. Dengan demikian, Anda akan mendapatkan rekomendasi tatalaksana dan konseling lebih dini jika didapatkan adanya gangguan kognitif dengan/tanpa adanya polimorfisme gen MTHFR C677T.
Hasil pemeriksaan tersebut memerlukan waktu untuk pengolahan dan interpretasi oleh Peneliti sebelum dapat disampaikan kepada partisipan. **Untuk itu, Anda dimohon memberikan nomor/alamat kontak yang dapat dihubungi**.
Semua pemeriksaan yang dilakukan untuk kepentingan penelitian ini dilakukan secara **cuma-cuma dan tidak dipungut biaya apapun**.

Prosedur pemeriksaan
Pada penelitian ini, dilakukan pengambilan sampel darah vena setelah Anda melakukan puasa selama 12 jam. Pengambilan sampel darah akan dilakukan secara aseptik oleh tenaga laboran yang terlatih. Selanjutnya, akan dilakukan pengisian kuisioner yang berisi informasi yang berisi identitas Anda, riwayat stroke iskemik, karakteristik klinik, dan karakteristik demografik yang Anda miliki. Data riwayat stroke iskemik yang dikumpulkan meliputi awitan terjadinya stroke iskemik, lokasi dan ukuran

infark berdasarkan hasil pemeriksaan CT scan kepala, dan pengobatan yang diperoleh dan dikonsumsi saat ini. Data karakteristik klinik yang dikumpulkan meliputi riwayat hipertensi, diabetes melitus, dislipidemia, obesitas sentral, merokok, dan fibrilasi atrium. Selanjutnya dilakukan pemeriksaan fungsi kognitif, yaitu dengan pemeriksaan menggunakan instrumen MoCA-INA. Pada pemeriksaan ini, Anda diberikan serangkaian tugas yang harus diselesaikan, umumnya dalam waktu 10-15 menit. Serangkaian tugas tersebut memiliki poin, sesuai dengan yang tertera dalam instrumen MoCA-INA tersebut.

Risiko

Pemeriksaan fungsi kognitif memiliki risiko minimal. Risiko yang bisa terjadi adalah terjadinya infeksi akibat masuknya agen infeksi pada tempat tusukan jarum sewaktu dilakukan pengambilan sampel darah vena. Risiko tersebut akan ditekan seminimal mungkin, dimana pengambilan sampel darah vena dikerjakan oleh tenaga laboran terlatih dan dikerjakan secara aseptik. Apabila di tengah proses pengambilan data kesehatan, Anda merasa tidak nyaman, anda dapat mengundurkan diri dari penelitian ini. Tidak ada konsekuensi apapun secara sosial, legal maupun ekonomi yang akan dikenakan apabila anda memilih untuk mundur.

Kerahasiaan

Hasil pemeriksaan hanya diketahui oleh Peneliti, Tim Peneliti dan Anda sendiri. Identitas dan data lengkap Anda akan dirahasiakan dalam laporan penelitian maupun publikasi.

Masalah dan Keluhan

Jika terjadi masalah, efek samping, atau pertanyaan yang ditimbulkan oleh prosedur penelitian, Anda dapat menghubungi Peneliti, atas nama Herpan Syafii Harahap (nomer HP. 08175770062). Peneliti akan merespon keluhan dan mencoba mencari solusi atas permasalahan yang disampaikan.

PENELITI

Herpan Syafii Harahap

Lampiran 4. Formulir Persetujuan

FORMULIR PERSETUJUAN SETELAH PENJELASAN

Saya yang bertandatangan di bawah ini :
Nama : .....
Umur : .....
Alamat : .....
.....

setelah mendengar/membaca dan mendapatkan informasi mengenai tujuan, manfaat, prosedur, dan risiko penelitian, telah memahami sepenuhnya informasi tersebut dan dengan ini menyatakan kesediaan untuk berpartisipasi dalam penelitian tersebut.

Saya sadar bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan dan saya berhak untuk menolak ikut atau mengundurkan diri dari partisipasi dalam penelitian ini. Saya berhak bertanya atau meminta penjelasan pada peneliti bila masih ada hal yang belum jelas atau masih ada hal yang ingin saya ketahui tentang penelitian ini.

Saya juga memahami bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini akan ditanggung oleh peneliti. Saya percaya bahwa keamanan dan kerahasiaan data penelitian akan terjamin dan saya dengan ini menyetujui semua data saya yang dihasilkan pada penelitian ini untuk disajikan dalam bentuk lisan maupun tulisan.

	Nama	**Tanda tangan**	**Tgl/Bln/Thn**
Responden	……..	……..	……..
Saksi 1	……..	…….....	…….....
Saksi 2	……..	…….....	……..

Penanggung Jawab Penelitian:

Nama : .....
Alamat : .....
Tlp : .....
Tanda tangan : .....

Lampiran 5. Instrumen Beck Depression Inventory – II (BDI-II)

BECK DEPRESSION INVENTORY (BDI) - II

Pilihlah satu iawaban yang sesuai dengan keadaan anda

1. A. Saya tidak merasa sedih
   B. Saya merasa sedih
   C. Saya sedih dan murung sepanjang waktu dan tidak bisa menghilangkan perasaan itu
   D. Saya demikian sedih atau tidak bahagia sehingga saya tidak tahan lagi rasanya

2. A. Saya tidak terlalu berkecil hati mengenai masa depan
   B. Saya merasa kecil hati mengenai masa depan
   C. Saya merasa bahwa tidak ada satupun yang dapat saya harapkan
   D. Saya merasa bahwa masa depan saya tanpa harapan dan bahwa semuanya tidak akan dapat membaik

3. A. Saya tidak menganggap diri saya sebagai orang yang gagal
   B. Saya merasa bahwa saya telah gagal lebih daripada kebanyakan orang
   C. Saat saya mengingat masa lalu, maka yang teringat oleh saya hanyalah kegagalan
   D. Saya merasa bahwa saya adalah seorang yang gagal total

4. A. Saya mendapat banyak kepuasan dari hal-hal yang biasa saya lakukan
   B. Saya tidak dapat lagi mendapat kepuasan dari hal-hal yang biasa saya lakukan
   C. Saya tidak mendapat kepuasan dari apapun lagi
   D. Saya rnerasa tidak puas atau bosan dengan segalanya

5. A. Saya tidak terlalu merasa bersalah
   B. Saya merasa bersalah di sebagian waktu saya
   C. Saya agak merasa bersalah di sebagian besar waktu
   D. Saya merasa bersalah sepanjang waktu

6. A. Saya tidak merasa seolah saya sedang dihukum
   B. Saya merasa mungkin saya sedang dihukum
   C. Saya pikir saya akan dihukum
   D. Saya merasa bahwa saya sedang dihukum

7. A. Saya tidak merasa kecewa terhadap diri saya sendiri

B. Saya kecewa dengan diri saya sendiri
C. Saya muak terhadap diri saya sendiri
D. Saya membenci diri saya sendiri

8. A. Saya tidak merasa lebih buruk dari pada orang lain
B. Saya mencela diri saya karena kelemahan dan kesalahan saya
C. Saya menyalahkan diri saya sepanjang waktu karena kesalahan-kesalahan saya
D. Saya menyalahkan diri saya untuk semua hal buruk yang terjadi

9. A. Saya tidak punya sedikitpun pikiran untuk bunuh diri
B. Saya mempunyai pikiran-pikiran untuk bunuh diri, namun saya tidak akan melakukannya
C. Saya ingin bunuh diri
D. Saya akan bunuh diri jika saya punya kesempatan

10. A. Saya tidak lebih banyak menangis dibandingkan biasanya
B. Sekarang saya lebih banyak menangis dari pada sebelumnya
C. Sekarang saya menangis sepanjang waktu
D. Biasanya saya rnampu menangis, namun kini saya tidak dapat lagi menangis walaupun saya menginginkannya

11. A, Saya tidak lebih terganggu oleh berbagai hal dibandingkan biasanya
B. Saya sedikit lebih pemarah dari pada biasanya akhir-akhir ini
C. Saya agak jengkel atau terganggu di sebagian besar waktu saya
D. Saya merasa jengkel sepanjang waktu sekarang

12. A. Saya tidak kehilangan minat saya terhadap orang lain
B. Saya agak kurang berminat terhadap orang lain dibanding biasanya
C. Saya kehilangan hampir seluruh minat saya pada orang lain
D. Saya telah kehilangan seluruh minat saya pada orang lain

13. A. Saya mengambil keputusan-keputusan hampir sama baiknya dengan yang biasa saya lakukan
B. Saya menunda mengambil keputusan-keputusan begiiu sering dari yang biasa saya lakukan
C. Saya mengalami kesulitan lebih besar dalam mengambil keputusan daripada sebelumnya
D. Saya sama sekali tidak dapat mengambil keputusan-keputusan lagi

14. A. Saya tidak merasa bahwa keadaan saya tampak lebih buruk dari biasanya
B. Saya khawatir saya tampak lebih tua atau tidak menarik
C.Saya merasa bahwa ada perubahan-perubahan yang menetap dalam penampilan saya sehingga membuat saya tampak tidak menarik
D. Saya yakin bahwa saya terlihat jelek

15. A. Saya dapat bekerja sama baiknya dengan waktu-waktu sebelumnya
    B. Saya membutuhkan suatu usaha ekstra untuk mulai melakukan sesuatu
    C. Saya harus memaksa diri sekuat tenaga untuk mulai melakukan sesuatu
    D. Saya tidak mampu mengerjakan apa pun lagi

16. A. Saya dapat tidur seperti biasanya
    B. Tidur saya tidak senyenyak biasanya
    C.Saya bangun 1-2 jam lebih awal dari biasanya dan merasa sukar sekali untuk bisa tidur kembali
    D.Saya bangun beberapa jam lebih awal dari biasanya dan tidak dapat tidur kembali

17. A. Saya tidak merasa lebih lelah dari biasanya
    B. Saya merasa lebih mudah lelah dari biasanya
    C, Saya merasa lelah setelah melakukan apa saja
    D. Saya terlalu lelah untuk melakukan apapun

18. A. Nafsu makan saya tidak lebih buruk dari biasanya
    B, Nafsu makan saya tidak sebaik biasanya
    C. Nafsu makan saya kini jauh lebih buruk
    D. Saya tak memiliki nafsu makan lagi

19. A. Berat badan saya tidak turun banyak atau bahkan tetap akhir-akhir ini
    B. Berat badan saya turun lebih dari 2,5 kg
    C. Berat badan saya turun lebih dari 5 kg
    D. Berat badan saya turun lebih dari 7.5 kg

20. A. Saya tidak lebih khawatir mengenai kesehatan saya dari pada biasanya
    B. Saya khawatir mengenai masalah-masalah fisik seperti rasa sakit dan tidak enak badan, atau perut mual atau sembelit
    C.Saya sangat cemas mengenai masalah-masalah fisik dan sukar untuk memikirkan banyak hal lainnya
    D.Saya begitu cemas mengenai masalah-masalah fisik saya sehingga tidak dapat berfikir tentang hal lainnya

21. A. Saya tidak melihat adanya perubahan dalam minat saya terhadap seks
    B. Saya kurang berminat di bidang seks dibandingkan biasanya
    C. Kini saya sangat kurang berminat terhadap seks
    D. Saya telah kehilangan minat terhadap seks sama sekali

Lampiran 6. Instrumen MoCA-Ina

INSTRUMEN PEMERIKSAAN MoCA-INA

<table>
<tr><td colspan="3">Visuospasial/ Eksekutif</td><td>Skor</td></tr>
<tr><td colspan="2"> 
</td><td> 
Contohlah Kubus</td><td>Gambar JAM
(jam 11 lebih 10 menit)</td><td></td></tr>
<tr><td colspan="2">[ ] [ ]</td><td>[ ] [ ] [ ]
Bentuk Angka Jarum</td><td>_ / 5</td></tr>
<tr><td colspan="3">Penamaan</td><td></td></tr>
<tr><td colspan="3">    </td><td></td></tr>
<tr><td colspan="3">[ ] [ ] [ ]</td><td>__/3</td></tr>
<tr><td colspan="3">Memori</td><td></td></tr>
<tr><td colspan="3"><table>
<tr><td></td><td>Wajah</td><td>Sutera</td><td>Masjid</td><td>Anggrek</td><td>Merah</td></tr>
<tr><td>I</td><td></td><td></td><td></td><td></td><td></td></tr>
<tr><td>II</td><td></td><td></td><td></td><td></td><td></td></tr>
</table>
Baca masing-masing kata. Subyek diminta mengulang. Lakukan 2 kali percobaan, meskipun percobaan pertama benar. Recall setelah 5 menit</td><td>Skor -</td></tr>
<tr><td colspan="3">Atensi</td><td></td></tr>
<tr><td>Baca deretan angka
(1 angka/ detik)</td><td>Subyek mengulang maju
Subyek mengulang mundur</td><td>[ ] 2 1 8 5 4
[ ] 7 4 2</td><td>__/2</td></tr>
<tr><td colspan="3">Baca deretan huruf. Subyek harus menepuk tiap disebutkan huruf “A”. Point 0 bila kesalahan ≥2
[ ] F B A C M N A A J K L B A F A K D E A A A J A J A M O F A A B</td><td>__/1</td></tr>
<tr><td colspan="3">Pengurangan 7 dari 100 [ ] 93 [ ] 86 [ ] 79 [ ] 72 [ ] 65
Bila benar 4 dari 5 (3 poin), bila benar 2 atau 3 (2 poin), bila benar 1 (1 poin), salah semua (0)</td><td>__/3</td></tr>
<tr><td colspan="3">Bahasa</td><td></td></tr>
<tr><td colspan="3">Ulangi: Wati membantu saya menyapu lantai hari ini
Tikus bersembunyi di bawah dipan ketika kucing datang</td><td>__/2</td></tr>
<tr><td colspan="3">Kelancaran berbahasa:
Katakan sebanyak mungkin kata yang anda ketahui berawalan dengan huruf S dalam 1 menit
[ ] _____ (N ≥ 11 kata)</td><td>__/1</td></tr>
<tr><td colspan="3">Berpikir abstrak contoh: kesamaan antara jeruk dan pisang adalah buah-buahan</td><td></td></tr>
<tr><td colspan="3">[ ] kereta – sepeda [ ] jam – penggaris</td><td>__/2</td></tr>
</table>

Memori tertunda Skor hanya bila tanpa petunjuk maupun pilihan	Recall	Wajah [ ]	Sutera [ ]	Masjid [ ]	Anggrek [ ]	Merah [ ]	__/5
	Petunjuk						
	Pilihan						
Orientasi: [ ] tanggal [ ] bulan [ ] tahun [ ] hari [ ]tempat [ ] kota							__/6
Normal ≥ 26/30 (tambahkan 1 poin bila lama pendidikan ≤ 12 tahun) **TOTAL**							_/30

Lampiran 7. Instrumen Penilaian NIHSS

INSTRUMEN NIHSS

Komponen yang Dinilai		Skor	Keterangan
Tingkat Kesadaran	Sadar penuh	0	
	Mengantuk	1	
	Dibangunkan dengan rangsang nyeri (Stupor)	2	
	Tidak berespon (Koma)	3	
Pertanyaan untuk menilai tingkat kesadaran	Menjawab 2 pertanyaan dengan benar	0	Pertanyaan: Siapa nama anda? Dimana rumah anda?
	Menjawab 1 pertanyaan dengan benar	1	
	Tidak ada satupun jawaban yang benar	2	
Perintah untuk menilai kesadaran	Melakukan 2 perintah dengan benar	0	Pertanyaan: Angkat tangan kanan/kiri (yang tidak parese) Angkat tungkai kanan/kiri (yang tidak parese)
	Melakukan 1 perintah dengan benar	1	
	Tidak ada satupun perintah yang dilakukan dengan benar	2	
Tatapan mata	Normal	0	Hanya diperiksa gerak horisontal
	Kelumpuhan gerak bola mata sebagian	1	
	Kelumpuhan gerak bola mata total	2	
Lapang pandang	Normal	0	
	Hemianopsia minimal	1	
	Hemianopsia total	2	
	Hemianopsia bilateral	3	
Parese wajah	Normal	0	
	Parese minimal	1	
	Parese sebagian	2	
	Parese total	3	
Motorik lengan kiri	Tanpa pergeseran (drift)	0	
	Bergeser sebelum 10 detik	1	
	Jatuh sebelum 10 detik	2	
	Tidak ada upaya melawan gravitasi	3	
	Tidak ada gerakan sama sekali	4	
Motorik lengan kanan	Tanpa pergeseran (drift)	0	
	Bergeser sebelum 10 detik	1	
	Jatuh sebelum 10 detik	2	
	Tidak ada upaya melawan gravitasi	3	
	Tidak ada gerakan sama sekali	4	
Motorik tungkai kiri	Tanpa pergeseran (drift)	0	
	Bergeser sebelum 10 detik	1	
	Jatuh sebelum 10 detik	2	

	Tidak ada upaya melawan gravitasi	3	
	Tidak ada gerakan sama sekali	4	
Motorik tungkai kanan	Tanpa pergeseran (drift)	0	
	Bergeser sebelum 10 detik	1	
	Jatuh sebelum 10 detik	2	
	Tidak ada upaya melawan gravitasi	3	
	Tidak ada gerakan sama sekali	4	
Ataksia	Tidak ada	0	
	1 tungkai	1	
	2 tungkai	2	
Sensoris	Normal	0	
	Menurun minimal (hipoestesi)	1	
	Kehilangan sensoris (anestesi)	2	
Bahasa	Normal	0	
	Afasia ringan (gagap)	1	
	Afasia berat (berusaha mengucapkan tapi tidak bisa)	2	
	Tidak bisa bicara sama sekali (diam/afasia global)	3	
Disartria	Normal	0	
	Ringan	1	
	Berat	2	
Perhatian	Normal	0	
	Gangguan ringan	1	
	Gangguan berat	2	
Skor Total			

Catatan: Lingkarilah poin dari setiap komponen yang dinilai.

Lampiran 8. Hasil Pemeriksaan Elektroforesis








Ledder
50 bp
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
300 bp
200 bp
100 bp
50 bp


Ledder
50 bp
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
85
86
87
300 bp
200 bp
100 bp
50 bp


Ledder
50 bp
88
89
41
49
52
53
54
55
56
57
300 bp
200 bp
100 bp
50 bp

Lampiran 9. Hasil analisis polimorfisme gen MTHFR C677T dengan program *Human BLAT Search*





ACTIONS	QUERY	SCORE	START	END	QSIZE	IDENTITY	CHROM	STRAND	START	END	SPAN
browser details	YourSeq	191	1	201	201	96.5%	chr1	-	11796148	11796347	200
browser details	YourSeq	27	43	74	201	86.3%	chrX	+	100935495	100935524	30
browser details	YourSeq	23	132	155	201	100.0%	chr16	+	84157230	84157259	30
browser details	YourSeq	22	133	157	201	95.9%	chr18	-	76461877	76461902	26
browser details	YourSeq	21	144	164	201	100.0%	chr17	-	81116390	81116410	21
browser details	YourSeq	21	170	190	201	100.0%	chr6_GL000256v2_alt	+	3092487	3092507	21
browser details	YourSeq	21	170	190	201	100.0%	chr6_GL000255v2_alt	+	3049023	3049043	21
browser details	YourSeq	21	170	190	201	100.0%	chr6_GL000254v2_alt	+	3135085	3135105	21
browser details	YourSeq	21	170	190	201	100.0%	chr6_GL000252v2_alt	+	3040970	3040990	21
browser details	YourSeq	21	170	190	201	100.0%	chr6_GL000251v2_alt	+	3270436	3270456	21
browser details	YourSeq	21	170	190	201	100.0%	chr6_GL000250v2_alt	+	3125807	3125827	21
browser details	YourSeq	21	170	190	201	100.0%	chr6	+	31793196	31793216	21
browser details	YourSeq	21	48	70	201	86.4%	chr5	+	122012826	122012847	22
browser details	YourSeq	21	27	55	201	87.0%	chr5	+	53578731	53578758	28
browser details	YourSeq	21	109	142	201	95.7%	chr15	+	74830451	74830486	36
browser details	YourSeq	20	4	25	201	85.8%	chr1	-	157414176	157414196	21
browser details	YourSeq	20	36	55	201	100.0%	chr2	+	173470606	173470625	20

Alignment of YourSeq

YourSeq
Human.chr1
block1
together

cDNA YourSeq

```
CTTGAAGGAG AAGGaGTCTG CGGGAGtCGA TgTCATCATC AtGCAGCTTT  50
TCTTTGAGGC TGACACATTC TTCCGCTTTG TGAAGGCATG CACCGACATG  100
GtGCATCACT TGCCCCATCG TCCCCGGGAT CTTTCCCATC CAGGTGAGGG  150
GCCCAGGAGA GCCCATAAGC TCCCTCCACC CCACTCTCAC CGCACCGTCC  200
T
```

Genomic chr1 (reverse strand):

```
ttgaacaggt ggaggccagc ctctcctgac tgtcatccct attggcaggt  11796398
taccccaaag gccaccccga agcagggagc tttgaggctg acctgaagca  11796348
CTTGAAGGAG AAGGtGTCTG CGGGAGcCGA TtTCATCATC AcGCAGCTTT  11796298
TCTTTGAGGC TGACACATTC TTCCGCTTTG TGAAGGCATG CACCGACATG  11796248
GGCATCACTT GCCCCATCGT CCCCGGGATC TTTCCCATCC AGGTGAGGGG  11796198
CCCAGGAGAG CCCATAAGCT CCCTCCACCC CACTCTCACC GCACCGTCCT  11796148
cgcacaggct gggggctctg ggtggagtgc tgagttcgct gagttcttcc  11796098
cagatctcct ctcaggtcca gaacttgcac agcgttgctt ggccacccca  11796048
```

Side by Side Alignment

```
00000001 cttgaaggagaaggagtctgcgggagtcgatgtcatcatcatgcagcttt 00000050
<<<<<<<< ||||||||||||||| |||||||||| |||| ||||||||| |||||||| <<<<<<<<
11796347 cttgaaggagaaggtgtctgcgggagccgatttcatcatcacgcagcttt 11796298

00000051 tctttgaggctgacacattcttccgctttgtgaaggcatgcaccgacatg 00000100
<<<<<<<< ||||||||||||||||||||||||||||||||||||||||||||||||| <<<<<<<<
11796297 tctttgaggctgacacattcttccgctttgtgaaggcatgcaccgacatg 11796248

00000101 gtgcatcacttgccccatcgtccccgggatctttcccatccaggtgaggg 00000150
<<<<<<<< | ||||||||||||||||||||||||||||||||||||||||||||||| <<<<<<<<
11796247 g.gcatcacttgccccatcgtccccgggatctttcccatccaggtgaggg 11796199

00000151 gcccaggagagcccataagctccctccaccccactctcaccgcaccgtcc 00000200
<<<<<<<< ||||||||||||||||||||||||||||||||||||||||||||||||| <<<<<<<<
11796198 gcccaggagagcccataagctccctccaccccactctcaccgcaccgtcc 11796149

00000201 t 00000201
<<<<<<<< | <<<<<<<<
11796148 t 11796148
```




National Library of Medicine
National Center for Biotechnology Information
Log in
ClinVar Genomic variation as it relates to human health
Search ClinVar
Advanced search
About Access Submit Stats FTP Help
Was this helpful?
Follow Print Download
NM_005957.5(MTHFR):c.665C>T (p.Ala222Val)
Cite this record
FEEDBACK
Interpretation: drug response
Review status: reviewed by expert panel
Submissions: 18 (Most recent: Mar 31, 2021)
Last evaluated: May 14, 2018
Accession: VCV000003520.18
Variation ID: 3520
Description: single nucleotide variant
Variant details
Conditions
Gene(s)
NM_005957.5(MTHFR):c.665C>T (p.Ala222Val)
Allele ID: 18559
Variant type: single nucleotide variant
Variant length: 1 bp
Cytogenetic location: 1p36.22
Genomic location: 1: 11796321 (GRCh38) GRCh38 UCSC
1: 11856378 (GRCh37) GRCh37 UCSC
HGVS:
Nucleotide
Protein
Molecular consequence
NC_000001.10:g.11856378G>A
NC_000001.11:g.11796321G>A
NM_005957.5:c.665C>T MANE SELECT
NP_005948.3:p.Ala222Val
missense
... more HGVS
Protein change: A222V, A263V
Other names: MTHFR, 677C-T, ALA222VAL (rs1801133)
C667T
Canonical SPDI: NC_000001.11:11796320:G:A

Lampiran 10. Hasil Analisis Statistik

1. Data Karakteristik demografik, klinik, polimorfisme MTHFR C677T, dan tingkat kadar homosistein serum subjek penelitian

Frequencies

Statistics

		Age	YearsOfEducation	MoCAlnaScore	VisuospatialExecutive	Naming	Attention	Language	AbstractThinking	DelayedMemory	Orientation
N	Valid	87	87	87	87	87	87	87	87	87	87
	Missing	0	0	0	0	0	0	0	0	0	0
Mean		54.1264	12.0172	20.5632	3.4138	2.5977	4.6897	2.1609	.9540	1.0230	5.3448
Median		54.0000	12.0000	21.0000	4.0000	3.0000	5.0000	2.0000	1.0000	.0000	6.0000
Std. Deviation		7.02124	3.59865	5.62945	1.38557	.82771	1.30572	.96296	.86142	1.36379	1.05464
Range		30.00	13.50	25.00	5.00	4.00	5.00	3.00	2.00	4.00	6.00
Minimum		40.00	6.00	4.00	.00	.00	1.00	.00	.00	.00	.00
Maximum		70.00	19.50	29.00	5.00	4.00	6.00	3.00	2.00	4.00	6.00

Frequency Table

Age Cathegory

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	40-59 years old	67	77.0	77.0	77.0
	60-70 years old	20	23.0	23.0	100.0
	Total	87	100.0	100.0	

Gender Cathegory

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Male	63	72.4	72.4	72.4
	Female	24	27.6	27.6	100.0
	Total	87	100.0	100.0	

Occupation

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Non-workers	28	32.2	32.2	32.2
	Non-manual workers	39	44.8	44.8	77.0
	Manual workers	20	23.0	23.0	100.0
	Total	87	100.0	100.0	

Educational Level

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Elementary school graduate	19	21.8	21.8	21.8
	High school graduate	40	46.0	46.0	67.8
	Bachelor	28	32.2	32.2	100.0
	Total	87	100.0	100.0	

Lesion Side Cathegory

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Right Hemisphere	34	39.1	39.1	39.1
	Left Hemisphere	35	40.2	40.2	79.3
	Bilateral	18	20.7	20.7	100.0
	Total	87	100.0	100.0	

CigaretteSmoking

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Yes	34	39.1	39.1	39.1
	No	53	60.9	60.9	100.0
	Total	87	100.0	100.0	

Hypertension

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Yes	79	90.8	90.8	90.8
	No	8	9.2	9.2	100.0
	Total	87	100.0	100.0	

Diabetes

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Yes	33	37.9	37.9	37.9
	No	54	62.1	62.1	100.0
	Total	87	100.0	100.0	

Dyslipidemia

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Yes	53	60.9	60.9	60.9
	No	34	39.1	39.1	100.0
	Total	87	100.0	100.0	

Obesity

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Yes	34	39.1	39.1	39.1
	No	53	60.9	60.9	100.0
	Total	87	100.0	100.0	

Atrial Fibrillation

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Yes	7	8.0	8.0	8.0
	No	80	92.0	92.0	100.0
	Total	87	100.0	100.0	

MoCA-Ina Cathegory

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Cognitive decline	62	71.3	71.3	71.3
	Normal	25	28.7	28.7	100.0
	Total	87	100.0	100.0	

NIHSS

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Ringan (NIHSS <4)	65	74.7	74.7	74.7
	Sedang (NIHSS 4-15)	22	25.3	25.3	100.0
	Total	87	100.0	100.0	

MTHFR Cat

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	CC	65	74.7	74.7	74.7
	CT	20	23.0	23.0	97.7
	TT	2	2.3	2.3	100.0
	Total	87	100.0	100.0	

HCY Cat

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	NORMAL (< 13 umol/L)	78	89.7	89.7	89.7
	HIPERHOMOSISTEINMIA (>= 13 umol/L)	9	10.3	10.3	100.0
	Total	87	100.0	100.0	

Frequencies

Statistics

Homosistein

N	Valid	87
	Missing	0
Mean		5.0353
Median		2.4100
Std. Deviation		7.08710
Range		36.45
Minimum		.47
Maximum		36.92

2. Hubungan antara Polimorfisme Gen MTHFR C677T dengan Tingkat Kadar Homosistein Serum Subjek Penelitian

1.1. Uji Beda Frekuensi

One-Sample Kolmogorov-Smirnov Test

		Age	YearsOfEducation	Homosistein
N		87	87	87
Normal Parameters[a,b]	Mean	54.1264	12.0172	5.0353
	Std. Deviation	7.02124	3.59865	7.08710
Most Extreme Differences	Absolute	.059	.188	.356
	Positive	.052	.180	.356
	Negative	-.059	-.188	-.260
Test Statistic		.059	.188	.356
Asymp. Sig. (2-tailed)		.200[c,d]	.000[c]	.000[c]

a. Test distribution is Normal.
b. Calculated from data.
c. Lilliefors Significance Correction.
d. This is a lower bound of the true significance.

One-Sample Kolmogorov-Smirnov Test

		MoCA-Ina Score	Visuospatial Executive	Naming	Attention	Language	Abstract Thinking	Delayed Memory	Orientation
N		87	87	87	87	87	87	87	87
Normal Parameters[a,b]	Mean	20.5632	3.4138	2.5977	4.6897	2.1609	.9540	1.0230	5.3448
	Std. Deviation	5.62945	1.38557	.82771	1.30572	.96296	.86142	1.36379	1.05464
Most Extreme Differences	Absolute	.132	.193	.434	.238	.302	.257	.348	.307
	Positive	.082	.126	.302	.158	.192	.257	.348	.267
	Negative	-.132	-.193	-.434	-.238	-.302	-.233	-.227	-.307
Test Statistic		.132	.193	.434	.238	.302	.257	.348	.307
Asymp. Sig. (2-tailed)		.001[c]	.000[c]	.000[c]	.000[c]	.000[c]	.000[c]	.000[c]	.000[c]

a. Test distribution is Normal.
b. Calculated from data.
c. Lilliefors Significance Correction.

Crosstabs

HCYCat * MTHFRCat Crosstabulation

			MTHFRCat2		
			CC	CT/TT	Total
HCYCat	NORMAL (< 13 umol/L)	Count	62	16	78
		% within HCYCat	79.5%	20.5%	100.0%
		% within MTHFRCat2	95.4%	72.7%	89.7%
		% of Total	71.3%	18.4%	89.7%
	HYPERHOMOSISTEINMIA (>= 13 umol/L)	Count	3	6	9
		% within HCYCat	33.3%	66.7%	100.0%
		% within MTHFRCat2	4.6%	27.3%	10.3%
		% of Total	3.4%	6.9%	10.3%
Total		Count	65	22	87
		% within HCYCat	74.7%	25.3%	100.0%
		% within MTHFRCat2	100.0%	100.0%	100.0%
		% of Total	74.7%	25.3%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	9.098[a]	1	.003		
Continuity Correction[b]	6.819	1	.009		
Likelihood Ratio	7.775	1	.005		
Fisher's Exact Test				.007	.007
Linear-by-Linear Association	8.993	1	.003		
N of Valid Cases	87				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 2.28.
b. Computed only for a 2x2 table

1.2. Uji Beda Rerata

Descriptives

	MTHFRCat			Statistic	Std. Error
Homocysteine	CC	Mean		3.0645	.33303
		95% Confidence Interval for Mean	Lower Bound	2.3992	
			Upper Bound	3.7298	
		5% Trimmed Mean		2.6793	
		Median		2.3400	
		Variance		7.209	
		Std. Deviation		2.68494	
		Minimum		.47	
		Maximum		13.34	
		Range		12.87	
		Interquartile Range		.95	
		Skewness		2.699	.297
		Kurtosis		7.116	.586
	CT/TT	Mean		10.8582	2.48795
		95% Confidence Interval for Mean	Lower Bound	5.6842	
			Upper Bound	16.0322	
		5% Trimmed Mean		9.9211	
		Median		3.1250	
		Variance		136.178	
		Std. Deviation		11.66954	
		Minimum		1.97	
		Maximum		36.92	
		Range		34.95	

	Interquartile Range	17.04	
	Skewness	1.163	.491
	Kurtosis	.050	.953

Mann-Whitney Test

Ranks

	MTHFRCat	N	Mean Rank	Sum of Ranks
Homocysteine	CC	65	38.51	2503.00
	CT/TT	22	60.23	1325.00
	Total	87		

Test Statistics[a]

	Homocysteine
Mann-Whitney U	358.000
Wilcoxon W	2503.000
Z	-3.486
Asymp. Sig. (2-tailed)	.000

a. Grouping Variable: MTHFRCat

3. Hubungan antara Polimorfisme Gen MTHFR C677T dan kadar homosistein serum dengan Status Fungsi Kognitif Subjek Penelitian

1.1. Tahap Analisis Deskriptif

Crosstabs

MoCA-Ina Cathegory * MTHFR Cat Crosstabulation

			MTHFRCat2		
			CC	CT/TT	Total
MoCAInaCathegory	Cognitive decline	Count	45	17	62
		% within MoCAInaCathegory	72.6%	27.4%	100.0%
		% within MTHFRCat2	69.2%	77.3%	71.3%
		% of Total	51.7%	19.5%	71.3%
	Normal	Count	20	5	25
		% within MoCAInaCathegory	80.0%	20.0%	100.0%
		% within MTHFRCat2	30.8%	22.7%	28.7%
		% of Total	23.0%	5.7%	28.7%
Total		Count	65	22	87
		% within MoCAInaCathegory	74.7%	25.3%	100.0%
		% within MTHFRCat2	100.0%	100.0%	100.0%
		% of Total	74.7%	25.3%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.519[a]	1	.471		
Continuity Correction[b]	.201	1	.654		
Likelihood Ratio	.536	1	.464		
Fisher's Exact Test				.590	.333
Linear-by-Linear Association	.513	1	.474		
N of Valid Cases	87				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 6.32.
b. Computed only for a 2x2 table

Mann-Whitney Test

Ranks

	MTHFRCat2	N	Mean Rank	Sum of Ranks
MoCAInaScore	CC	65	45.85	2980.00
	CT/TT	22	38.55	848.00
	Total	87		
VisuospatialExecutive	CC	65	46.78	3041.00
	CT/TT	22	35.77	787.00
	Total	87		
Naming	CC	65	45.56	2961.50
	CT/TT	22	39.39	866.50
	Total	87		
Attention	CC	65	44.87	2916.50
	CT/TT	22	41.43	911.50
	Total	87		
Language	CC	65	44.95	2922.00
	CT/TT	22	41.18	906.00
	Total	87		
AbstractThinking	CC	65	43.60	2834.00
	CT/TT	22	45.18	994.00
	Total	87		
DelayedMemory	CC	65	45.53	2959.50
	CT/TT	22	39.48	868.50
	Total	87		
Orientation	CC	65	44.35	2882.50
	CT/TT	22	42.98	945.50
	Total	87		

Test Statistics[a]

	MoCA-Ina Score	Visuospatial Executive	Naming	Attention	Language	Abstract Thinking	Delayed Memory	Orientation
Mann-Whitney U	595.000	534.000	613.500	658.500	653.000	689.000	615.500	692.500
Wilcoxon W	848.000	787.000	866.500	911.500	906.000	2834.000	868.500	945.500
Z	-1.178	-1.818	-1.281	-.573	-.654	-.271	-1.084	-.249
Asymp. Sig. (2-tailed)	.239	.069	.200	.567	.513	.787	.278	.804

a. Grouping Variable: MTHFRCat2

Crosstabs

MoCAInaCathegory * HCYCat Crosstabulation

			HCYCat		
			NORMAL (< 13 umol/L)	HYPER HOMOSISTEINMIA (>= 13 umol/L)	Total
MoCA-Ina Cathegory	Cognitive decline	Count	56	6	62
		% within MoCAInaCathegory	90.3%	9.7%	100.0%
		% within HCYCat	71.8%	66.7%	71.3%
		% of Total	64.4%	6.9%	71.3%
	Normal	Count	22	3	25
		% within MoCAInaCathegory	88.0%	12.0%	100.0%
		% within HCYCat	28.2%	33.3%	28.7%
		% of Total	25.3%	3.4%	28.7%
Total		Count	78	9	87
		% within MoCAInaCathegory	89.7%	10.3%	100.0%
		% within HCYCat	100.0%	100.0%	100.0%
		% of Total	89.7%	10.3%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.104[a]	1	.748		
Continuity Correction[b]	.000	1	1.000		
Likelihood Ratio	.101	1	.751		
Fisher's Exact Test				.712	.508
Linear-by-Linear Association	.102	1	.749		
N of Valid Cases	87				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 2.59.
b. Computed only for a 2x2 table

Mann-Whitney Test

Ranks

	HCYCat	N	Mean Rank	Sum of Ranks
MoCAInaScore	NORMAL (< 13 umol/L)	78	43.90	3424.50
	HIPERHOMOSISTEINEMIA (>= 13 umol/L)	9	44.83	403.50
	Total	87		
VisuospatialExecutive	NORMAL (< 13 umol/L)	78	45.83	3575.00
	HIPERHOMOSISTEINEMIA (>= 13 umol/L)	9	28.11	253.00
	Total	87		
Naming	NORMAL (< 13 umol/L)	78	44.85	3498.50
	HIPERHOMOSISTEINEMIA (>= 13 umol/L)	9	36.61	329.50
	Total	87		
Attention	NORMAL (< 13 umol/L)	78	44.37	3461.00
	HIPERHOMOSISTEINEMIA (>= 13 umol/L)	9	40.78	367.00
	Total	87		
Language	NORMAL (< 13 umol/L)	78	43.58	3399.00

	HIPERHOMOSISTEINEMIA (>= 13 umol/L)	9	47.67	429.00
	Total	87		
AbstractThinking	NORMAL (< 13 umol/L)	78	43.14	3365.00
	HIPERHOMOSISTEINMIA (>= 13 umol/L)	9	51.44	463.00
	Total	87		
DelayedMemory	NORMAL (< 13 umol/L)	78	43.01	3355.00
	HIPERHOMOSISTEINEMIA (>= 13 umol/L)	9	52.56	473.00
	Total	87		
Orientation	NORMAL (< 13 umol/L)	78	43.64	3404.00
	HIPERHOMOSISTEINEMIA (>= 13 umol/L)	9	47.11	424.00
	Total	87		

Test Statistics[a]

	MoCA-Ina Score	Visuospatial Executive	Naming	Attention	Language	Abstract Thinking	Delayed Memory	Orientation
Mann-Whitney U	343.500	208.000	284.500	322.000	318.000	284.000	274.000	323.000
Wilcoxon W	3424.500	253.000	329.500	367.000	3399.000	3365.000	3355.000	3404.000
Z	-.105	-2.050	-1.198	-.420	-.497	-.995	-1.197	-.442
Asymp. Sig. (2-tailed)	.916	.040	.231	.675	.619	.320	.231	.659

a. Grouping Variable: HCYCat

Nonparametric Correlations

Correlations

			MoCA-Ina Score	Visuospatial Executive	Naming	Attention	Language	Abstract Thinking	Delayed Memory	Orientation	Hcy
Spearman's rho	MoCA-Ina-Score	Correlation Coefficient	1.000	.794**	.635**	.776**	.724**	.628**	.704**	.664**	-.118
		Sig. (2-tailed)	.	.000	.000	.000	.000	.000	.000	.000	.274
		N	87	87	87	87	87	87	87	87	87
	Visuospatial Executive	Correlation Coefficient	.794**	1.000	.467**	.650**	.548**	.496**	.350**	.460**	-.330**
		Sig. (2-tailed)	.000	.	.000	.000	.000	.000	.001	.000	.002
		N	87	87	87	87	87	87	87	87	87
	Naming	Correlation Coefficient	.635**	.467**	1.000	.479**	.552**	.183	.384**	.383**	-.068
		Sig. (2-tailed)	.000	.000	.	.000	.000	.090	.000	.000	.531
		N	87	87	87	87	87	87	87	87	87
	Attention	Correlation Coefficient	.776**	.650**	.479**	1.000	.551**	.471**	.379**	.479**	-.273*
		Sig. (2-tailed)	.000	.000	.000	.	.000	.000	.000	.000	.010
		N	87	87	87	87	87	87	87	87	87
	Language	Correlation Coefficient	.724**	.548**	.552**	.551**	1.000	.395**	.374**	.507**	.035
		Sig. (2-tailed)	.000	.000	.000	.000	.	.000	.000	.000	.745
		N	87	87	87	87	87	87	87	87	87
	Abstract Thinking	Correlation Coefficient	.628**	.496**	.183	.471**	.395**	1.000	.363**	.291**	-.041
		Sig. (2-tailed)	.000	.000	.090	.000	.000	.	.001	.006	.707
		N	87	87	87	87	87	87	87	87	87

	Delayed Memory	Correlation Coefficient	.704**	.350**	.384**	.379**	.374**	.363**	1.000	.401**	-.035
		Sig. (2-tailed)	.000	.001	.000	.000	.000	.001	.	.000	.750
		N	87	87	87	87	87	87	87	87	87
	Orientation	Correlation Coefficient	.664**	.460**	.383**	.479**	.507**	.291**	.401**	1.000	.095
		Sig. (2-tailed)	.000	.000	.000	.000	.000	.006	.000	.	.379
		N	87	87	87	87	87	87	87	87	87
	Hcy	Correlation Coefficient	-.118	-.330**	-.068	-.273*	.035	-.041	-.035	.095	1.000
		Sig. (2-tailed)	.274	.002	.531	.010	.745	.707	.750	.379	.
		N	87	87	87	87	87	87	87	87	87

**. Correlation is significant at the 0.01 level (2-tailed).

*. Correlation is significant at the 0.05 level (2-tailed).

1.2. Tahap Uji Regeresi Logistik Sederhana

Logistic Regression

Variables in the Equation

		B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I.for EXP(B)	
								Lower	Upper
Step 1[a]	Age Cathegory(1)	1.019	.678	2.258	1	.133	2.770	.733	10.465
	Constant	-1.735	.626	7.673	1	.006	.176		

a. Variable(s) entered on step 1: AgeCathegory.

Variables in the Equation

		B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I.for EXP(B)	
								Lower	Upper
Step 1[a]	Gender Cathegory(1)	.570	.571	.995	1	.318	1.767	.577	5.411
	Constant	-1.335	.503	7.055	1	.008	.263		

a. Variable(s) entered on step 1: GenderCathegory.

Variables in the Equation

		B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I.for EXP(B)	
								Lower	Upper
Step 1[a]	Occupation			4.369	2	.113			
	Occupation(1)	-.944	.728	1.684	1	.194	.389	.093	1.619
	Occupation(2)	.377	.589	.411	1	.522	1.458	.460	4.622
	Constant	-.847	.488	3.015	1	.082	.429		

a. Variable(s) entered on step 1: Occupation2.

Variables in the Equation

		B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I.for EXP(B)	
								Lower	Upper
Step 1[a]	Educational Level			2.973	2	.226			
	Educational Level(1)	-1.239	.739	2.812	1	.094	.290	.068	1.232
	Educational Level(2)	-.534	.525	1.037	1	.309	.586	.210	1.639
	Constant	-.435	.387	1.266	1	.261	.647		

a. Variable(s) entered on step 1: EducationalLevel.

Variables in the Equation

		B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I.for EXP(B)	
								Lower	Upper
Step 1[a]	Infark Size Cathegory(1)	1.469	.790	3.455	1	.063	4.344	.923	20.446
	Constant	-2.140	.748	8.196	1	.004	.118		

a. Variable(s) entered on step 1: InfarkSizeCathegory.

Variables in the Equation

		B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I.for EXP(B)	
								Lower	Upper
Step 1[a]	LesionSideCathegory			.016	2	.992			
	LesionSideCathegory(1)	.080	.647	.015	1	.902	1.083	.305	3.850
	LesionSideCathegory(2)	.039	.646	.004	1	.952	1.040	.293	3.687
	Constant	-.956	.526	3.297	1	.069	.385		

a. Variable(s) entered on step 1: LesionSideCathegory.

Variables in the Equation

		B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I.for EXP(B)	
								Lower	Upper
Step 1[a]	Cigarette Smoking(1)	.054	.484	.012	1	.911	1.056	.408	2.728
	Constant	-.930	.305	9.292	1	.002	.395		

a. Variable(s) entered on step 1: CigaretteSmoking.

Variables in the Equation

		B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I.for EXP(B)	
								Lower	Upper
Step 1[a]	Hypertension(1)	-.441	.772	.326	1	.568	.643	.142	2.922
	Constant	-.511	.730	.489	1	.484	.600		

a. Variable(s) entered on step 1: Hypertension.

Variables in the Equation

		B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I.for EXP(B)	
								Lower	Upper
Step 1[a]	Diabetes(1)	.123	.486	.064	1	.801	1.130	.436	2.928
	Constant	-.956	.304	9.891	1	.002	.385		

a. Variable(s) entered on step 1: Diabetes.

Variables in the Equation

		B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I.for EXP(B)	
								Lower	Upper
Step 1[a]	Dyslipidemia(1)	-.054	.484	.012	1	.911	.947	.367	2.448
	Constant	-.875	.376	5.410	1	.020	.417		

a. Variable(s) entered on step 1: Dyslipidemia.

Variables in the Equation

		B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I.for EXP(B)	
								Lower	Upper
Step 1[a]	Obesity(1)	.518	.480	1.162	1	.281	1.678	.655	4.303
	Constant	-1.124	.319	12.394	1	.000	.325		

a. Variable(s) entered on step 1: Obesity.

Variables in the Equation

		B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I.for EXP(B)	
								Lower	Upper
Step 1[a]	Atrial Fibrillation(1)	-.944	1.107	.727	1	.394	.389	.044	3.407
	Constant	-.847	.244	12.061	1	.001	.429		

a. Variable(s) entered on step 1: AtrialFibrillation.

1.3. Tahap Uji Regeresi Logistik Multipel

Variables in the Equation

		B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I.for EXP(B)	
								Lower	Upper
Step 1[a]	Educational Level			2.220	2	.330			
	Educational Level(1)	-1.298	.872	2.213	1	.137	.273	.049	1.510
	Educational Level(2)	-.520	.690	.568	1	.451	.594	.154	2.300
	Age Cathegory(1)	1.367	.755	3.281	1	.070	3.925	.894	17.237
	Occupation			1.375	2	.503			
	Occupation(1)	-.634	.788	.647	1	.421	.530	.113	2.487
	Occupation(2)	.206	.742	.077	1	.781	1.229	.287	5.256
	InfarkSizeCathegory(1)	1.710	.827	4.280	1	.039	5.532	1.094	27.963
	Constant	-2.907	1.321	4.844	1	.028	.055		

a. Variable(s) entered on step 1: EducationalLevel, AgeCathegory, Occupation2, InfarkSizeCathegory.

4. Hubungan antara Status Fungsi Kognitif, Polimorfisme Gen MTHFR C677T, dan Tingkat Kadar homosistein Serum dengan Tingkat Kapasitas Fungsional Subjek Penelitian

Crosstabs

MoCAInaCathegory * NIHSS2 Crosstabulation

			NIHSS		
			Ringan (NIHSS <4)	Sedang (NIHSS 4-15)	Total
MoCA-Ina Cathegory	Cognitive decline	Count	42	20	62
		% within MoCA-Ina Cathegory	67.7%	32.3%	100.0%
		% within NIHSS2	64.6%	90.9%	71.3%
		% of Total	48.3%	23.0%	71.3%
	Normal	Count	23	2	25
		% within MoCA-Ina Cathegory	92.0%	8.0%	100.0%
		% within NIHSS2	35.4%	9.1%	28.7%
		% of Total	26.4%	2.3%	28.7%
Total		Count	65	22	87
		% within MoCA-Ina Cathegory	74.7%	25.3%	100.0%
		% within NIHSS2	100.0%	100.0%	100.0%
		% of Total	74.7%	25.3%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	5.549[a]	1	.018		
Continuity Correction[b]	4.339	1	.037		
Likelihood Ratio	6.482	1	.011		
Fisher's Exact Test				.027	.014
Linear-by-Linear Association	5.485	1	.019		
N of Valid Cases	87				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 6.32.
b. Computed only for a 2x2 table

Crosstab

			NIHSS2		
			Ringan (NIHSS <4)	Sedang (NIHSS 4-15)	Total
MTHFRCat2	CC	Count	49	16	65
		% within MTHFRCat2	75.4%	24.6%	100.0%
		% within NIHSS2	75.4%	72.7%	74.7%
		% of Total	56.3%	18.4%	74.7%
	CT/TT	Count	16	6	22
		% within MTHFRCat2	72.7%	27.3%	100.0%
		% within NIHSS2	24.6%	27.3%	25.3%
		% of Total	18.4%	6.9%	25.3%
Total		Count	65	22	87
		% within MTHFRCat2	74.7%	25.3%	100.0%
		% within NIHSS2	100.0%	100.0%	100.0%
		% of Total	74.7%	25.3%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.061[a]	1	.804		
Continuity Correction[b]	.000	1	1.000		
Likelihood Ratio	.061	1	.805		
Fisher's Exact Test				.784	.505
Linear-by-Linear Association	.061	1	.805		
N of Valid Cases	87				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.56.

b. Computed only for a 2x2 table

Crosstab

			NIHSS2		
			Ringan (NIHSS <4)	Sedang (NIHSS 4-15)	Total
HCYCat	NORMAL (< 13 umol/L)	Count	57	21	78
		% within HCYCat	73.1%	26.9%	100.0%
		% within NIHSS2	87.7%	95.5%	89.7%
		% of Total	65.5%	24.1%	89.7%
	HYPERHOMOCYSTEINEMIA (>= 13 umol/L)	Count	8	1	9
		% within HCYCat	88.9%	11.1%	100.0%
		% within NIHSS2	12.3%	4.5%	10.3%
		% of Total	9.2%	1.1%	10.3%
Total		Count	65	22	87
		% within HCYCat	74.7%	25.3%	100.0%
		% within NIHSS2	100.0%	100.0%	100.0%
		% of Total	74.7%	25.3%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.068[a]	1	.301		
Continuity Correction[b]	.395	1	.530		
Likelihood Ratio	1.244	1	.265		
Fisher's Exact Test				.438	.279
Linear-by-Linear Association	1.056	1	.304		
N of Valid Cases	87				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 2.28.

b. Computed only for a 2x2 table

Lampiran 10. Data Subjek Penelitian

DATA SUBJEK PENELITIAN

No. Subjek	Rumah Sakit	No. RM	Nama	Umur (Th)	Gender	Tingkat Pendidikan	Pekerjaan	Ukuran Infark	Lokasi Infark	Kapasitas Fungsional	Skor moCA-Ina	Status fungsi Kognitif	*Kadar Homosistein*	*Polimorfisme MTHFR*
D-001	RSI SITI HAJAR	125877	IMK	54	LAKI-LAKI	SEKOLAH MENENGAH	TIDAK BEKERJA	KECIL	BILATERAL	SEDANG	19	MENURUN	NORMAL	WILD-TYPE
D-002	RSUD PROVINSI NTB	110075	IKN	64	LAKI-LAKI	SEKOLAH MENENGAH	TIDAK BEKERJA	KECIL	HEMISFER KANAN	SEDANG	14	MENURUN	NORMAL	WILD-TYPE
D-003	RSUD PROVINSI NTB	35075	RUS	60	LAKI-LAKI	SEKOLAH DASAR	MANUAL	KECIL	HEMISFER KANAN	RINGAN	14	MENURUN	NORMAL	WILD-TYPE
D-004	RSUD PROVINSI NTB	38357	MAH	61	LAKI-LAKI	SEKOLAH MENENGAH	NON-MANUAL	KECIL	BILATERAL	SEDANG	10	MENURUN	NORMAL	HETEROZIGOT
D-005	RSI SITI HAJAR	125439	SAH	61	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	HEMISFER KIRI	RINGAN	20	MENURUN	TINGGI	HOMOZIGOT
D-006	RSI SITI HAJAR	126377	NUR	53	PEREMPUAN	SEKOLAH DASAR	TIDAK BEKERJA	BESAR	BILATERAL	SEDANG	16	MENURUN	NORMAL	HETEROZIGOT
D-007	RSUD PROVINSI NTB	40315	AUS	40	LAKI-LAKI	SEKOLAH MENENGAH	MANUAL	BESAR	BILATERAL	SEDANG	22	MENURUN	NORMAL	HETEROZIGOT
D-008	RSUD PROVINSI NTB	41182	STA	54	PEREMPUAN	SEKOLAH MENENGAH	TIDAK BEKERJA	KECIL	HEMISFER KANAN	SEDANG	15	MENURUN	NORMAL	HETEROZIGOT
D-009	RSUD PROVINSI NTB	24829	IMT	64	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	HEMISFER KANAN	RINGAN	21	MENURUN	TINGGI	HETEROZIGOT
D-010	RSI SITI HAJAR	125012	SMH	44	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	BILATERAL	RINGAN	28	NORMAL	NORMAL	HETEROZIGOT
D-011	RSUD PROVINSI NTB	35203	WJK	59	LAKI-LAKI	SEKOLAH MENENGAH	NON-MANUAL	BESAR	HEMISFER KANAN	RINGAN	20	MENURUN	NORMAL	WILD-TYPE
D-012	RSUD PROVINSI NTB	41567	NAS	54	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	HEMISFER KANAN	RINGAN	26	NORMAL	NORMAL	HETEROZIGOT
D-013	RSI SITI HAJAR	125611	RMN	53	PEREMPUAN	SEKOLAH DASAR	TIDAK BEKERJA	KECIL	BILATERAL	RINGAN	6	MENURUN	NORMAL	WILD-TYPE
D-014	RSI SITI HAJAR	124246	IZM	49	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	BESAR	HEMISFER KIRI	RINGAN	10	MENURUN	NORMAL	WILD-TYPE

D-015	RSI SITI HAJAR	113391	KTM	65	PEREMPUAN	SEKOLAH MENENGAH	TIDAK BEKERJA	KECIL	BILATERAL	RINGAN	5	MENURUN	NORMAL	WILD-TYPE
D-016	RSUD PROVINSI NTB	43002	MJA	55	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	BILATERAL	SEDANG	26	NORMAL	NORMAL	WILD-TYPE
D-017	RSUD PROVINSI NTB	39869	ERN	47	PEREMPUAN	SEKOLAH MENENGAH	TIDAK BEKERJA	KECIL	HEMISFER KIRI	RINGAN	29	NORMAL	NORMAL	WILD-TYPE
D-018	RSI SITI HAJAR	127213	MRY	64	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	HEMISFER KIRI	RINGAN	19	MENURUN	NORMAL	WILD-TYPE
D-019	RSI SITI HAJAR	127145	HHM	60	LAKI-LAKI	SEKOLAH DASAR	MANUAL	BESAR	BILATERAL	RINGAN	22	MENURUN	NORMAL	WILD-TYPE
D-020	RSUD KOTA MATARAM	228892	BDS	55	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	HEMISFER KANAN	RINGAN	17	MENURUN	TINGGI	HETEROZIGOT
D-021	RSUD KOTA MATARAM	283527	MAZ	55	LAKI-LAKI	SEKOLAH MENENGAH	MANUAL	KECIL	BILATERAL	RINGAN	26	NORMAL	NORMAL	WILD-TYPE
D-022	RSUD KOTA MATARAM	142622	SLN	44	LAKI-LAKI	SEKOLAH MENENGAH	MANUAL	KECIL	HEMISFER KANAN	RINGAN	14	MENURUN	NORMAL	WILD-TYPE
D-023	RSUD KOTA MATARAM	350842	MYD	52	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	HEMISFER KIRI	RINGAN	28	NORMAL	NORMAL	WILD-TYPE
D-024	RSI SITI HAJAR	81372	LSD	54	LAKI-LAKI	SEKOLAH MENENGAH	NON-MANUAL	KECIL	BILATERAL	RINGAN	28	NORMAL	TINGGI	WILD-TYPE
D-025	RSI SITI HAJAR	115778	SBD	54	LAKI-LAKI	SEKOLAH MENENGAH	MANUAL	KECIL	HEMISFER KIRI	RINGAN	23	MENURUN	NORMAL	HETEROZIGOT
D-026	RSI SITI HAJAR	129223	JLD	50	LAKI-LAKI	SEKOLAH DASAR	MANUAL	KECIL	BILATERAL	RINGAN	21	MENURUN	NORMAL	HETEROZIGOT
D-027	RSI SITI HAJAR	128548	JNS	43	LAKI-LAKI	SEKOLAH DASAR	TIDAK BEKERJA	BESAR	HEMISFER KANAN	SEDANG	17	MENURUN	NORMAL	WILD-TYPE
D-029	RSI SITI HAJAR	128127	ARR	53	LAKI-LAKI	SEKOLAH MENENGAH	MANUAL	BESAR	HEMISFER KIRI	RINGAN	16	MENURUN	NORMAL	HETEROZIGOT
D-030	RSI SITI HAJAR	130449	NKP	40	PEREMPUAN	SEKOLAH MENENGAH	NON-MANUAL	BESAR	HEMISFER KIRI	RINGAN	17	MENURUN	NORMAL	HETEROZIGOT
D-031	RSUD PROVINSI NTB	47182	SYF	42	LAKI-LAKI	SEKOLAH MENENGAH	MANUAL	KECIL	HEMISFER KIRI	RINGAN	26	NORMAL	NORMAL	WILD-TYPE
D-032	RSI SITI HAJAR	66812	LDY	63	PEREMPUAN	SEKOLAH MENENGAH	TIDAK BEKERJA	KECIL	HEMISFER KANAN	RINGAN	24	MENURUN	NORMAL	WILD-TYPE
D-033	RSI SITI HAJAR	129875	KML	42	LAKI-LAKI	SEKOLAH MENENGAH	MANUAL	KECIL	HEMISFER KANAN	RINGAN	27	MENURUN	NORMAL	WILD-TYPE
D-034	RSI SITI HAJAR	101362	AKW	47	LAKI-LAKI	SEKOLAH MENENGAH	MANUAL	KECIL	HEMISFER KIRI	RINGAN	26	NORMAL	NORMAL	WILD-TYPE
D-035	RSI SITI HAJAR	130998	RHN	52	LAKI-LAKI	SEKOLAH MENENGAH	NON-MANUAL	KECIL	HEMISFER KIRI	SEDANG	15	MENURUN	NORMAL	HETEROZIGOT
D-036	RSUD KOTA MATARAM	348131	RNT	48	PEREMPUAN	SEKOLAH MENENGAH	TIDAK BEKERJA	BESAR	BILATERAL	RINGAN	4	MENURUN	TINGGI	HETEROZIGOT

D-037	RSI SITI HAJAR	113291	BQJ	58	PEREMPUAN	SEKOLAH MENENGAH	NON-MANUAL	KECIL	HEMISFER KANAN	RINGAN	26	NORMAL	TINGGI	HETEROZIGOT
D-038	RSUD PROVINSI NTB	50321	RLH	58	PEREMPUAN	PENDIDIKAN TINGGI	TIDAK BEKERJA	KECIL	HEMISFER KIRI	SEDANG	15	MENURUN	TINGGI	HOMOZIGOT
D-039	RSI SITI HAJAR	132250	ZAB	49	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	BESAR	HEMISFER KIRI	RINGAN	26	NORMAL	NORMAL	HETEROZIGOT
D-040	RSUD PROVINSI NTB	54699	MSA	50	LAKI-LAKI	SEKOLAH MENENGAH	MANUAL	KECIL	HEMISFER KIRI	RINGAN	23	MENURUN	NORMAL	HETEROZIGOT
D-041	RSUD PROVINSI NTB	52485	FTH	59	PEREMPUAN	SEKOLAH DASAR	TIDAK BEKERJA	BESAR	HEMISFER KIRI	RINGAN	15	MENURUN	NORMAL	HETEROZIGOT
D-042	RSUD KOTA MATARAM	359274	MRD	46	LAKI-LAKI	SEKOLAH MENENGAH	NON-MANUAL	KECIL	HEMISFER KANAN	RINGAN	26	NORMAL	NORMAL	HETEROZIGOT
D-043	RSI SITI HAJAR	132680	IKD	54	LAKI-LAKI	SEKOLAH MENENGAH	NON-MANUAL	BESAR	HEMISFER KANAN	RINGAN	23	MENURUN	NORMAL	WILD-TYPE
D-044	RSI SITI HAJAR	94279	DMN	60	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	HEMISFER KANAN	RINGAN	22	MENURUN	NORMAL	WILD-TYPE
D-045	RSI SITI HAJAR	132615	IWD	70	LAKI-LAKI	SEKOLAH MENENGAH	TIDAK BEKERJA	BESAR	BILATERAL	RINGAN	17	MENURUN	NORMAL	WILD-TYPE
D-046	RSUD KOTA MATARAM	193714	MHN	55	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	BESAR	HEMISFER KANAN	RINGAN	20	MENURUN	NORMAL	WILD-TYPE
D-047	RSUD KOTA MATARAM	194768	MRP	48	LAKI-LAKI	SEKOLAH MENENGAH	NON-MANUAL	BESAR	HEMISFER KIRI	SEDANG	17	MENURUN	NORMAL	WILD-TYPE
D-048	RSI SITI HAJAR	108713	DDS	61	LAKI-LAKI	PENDIDIKAN TINGGI	TIDAK BEKERJA	BESAR	BILATERAL	RINGAN	23	MENURUN	NORMAL	HETEROZIGOT
D-049	RSI SITI HAJAR	134513	KNZ	58	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	HEMISFER KANAN	SEDANG	26	NORMAL	NORMAL	WILD-TYPE
D-050	RSUD PROVINSI NTB	55515	SMD	57	PEREMPUAN	PENDIDIKAN TINGGI	NON-MANUAL	BESAR	HEMISFER KANAN	SEDANG	26	NORMAL	NORMAL	WILD-TYPE
D-051	RSI SITI HAJAR	126709	BDN	60	LAKI-LAKI	PENDIDIKAN TINGGI	TIDAK BEKERJA	KECIL	HEMISFER KANAN	SEDANG	21	MENURUN	NORMAL	WILD-TYPE
D-052	RSI SITI HAJAR	129972	ASR	50	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	BILATERAL	RINGAN	17	MENURUN	NORMAL	WILD-TYPE
D-053	RSI SITI HAJAR	133956	SMF	61	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	HEMISFER KANAN	RINGAN	22	MENURUN	NORMAL	WILD-TYPE
D-054	RSUD PROVINSI NTB	551835	ARF	56	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	HEMISFER KIRI	SEDANG	16	MENURUN	NORMAL	WILD-TYPE
D-055	RSUD KOTA MATARAM	51721	PSH	69	LAKI-LAKI	SEKOLAH MENENGAH	TIDAK BEKERJA	KECIL	HEMISFER KANAN	SEDANG	12	MENURUN	NORMAL	WILD-TYPE
D-056	RSI SITI HAJAR	135807	RIP	52	LAKI-LAKI	SEKOLAH MENENGAH	TIDAK BEKERJA	KECIL	BILATERAL	RINGAN	17	MENURUN	NORMAL	WILD-TYPE

D-057	RSUD PROVINSI NTB	612 41	ABD	58	LAKI-LAKI	SEKOLAH DASAR	NON-MANUAL	KECIL	HEMISFER KIRI	SEDANG	14	MENURUN	NORMAL	WILD-TYPE
D-058	RSUD PROVINSI NTB	628 06	HRH	42	PEREMPUAN	SEKOLAH DASAR	TIDAK BEKERJA	KECIL	HEMISFER KIRI	SEDANG	16	MENURUN	NORMAL	WILD-TYPE
D-059	RSUD KOTA MATARAM	367 324	SBR	52	LAKI-LAKI	SEKOLAH MENENGAH	NON-MANUAL	KECIL	HEMISFER KIRI	RINGAN	19	MENURUN	NORMAL	WILD-TYPE
D-060	RSUD KOTA MATARAM	367 621	ILH	57	LAKI-LAKI	SEKOLAH MENENGAH	NON-MANUAL	KECIL	HEMISFER KANAN	RINGAN	27	NORMAL	NORMAL	WILD-TYPE
D-061	RSI SITI HAJAR	136 877	NSM	58	LAKI-LAKI	SEKOLAH MENENGAH	NON-MANUAL	KECIL	HEMISFER KIRI	RINGAN	26	NORMAL	NORMAL	WILD-TYPE
D-062	RSI SITI HAJAR	136 653	JTR	54	PEREMPUAN	SEKOLAH MENENGAH	TIDAK BEKERJA	KECIL	HEMISFER KANAN	RINGAN	17	MENURUN	NORMAL	WILD-TYPE
D-063	RSUD KOTA MATARAM	361 275	AHS	61	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	HEMISFER KIRI	RINGAN	26	NORMAL	NORMAL	WILD-TYPE
D-064	RSI SITI HAJAR	137 615	TNR	54	PEREMPUAN	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	HEMISFER KIRI	RINGAN	21	MENURUN	NORMAL	WILD-TYPE
D-065	RSI SITI HAJAR	369 179	AST	52	PEREMPUAN	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	HEMISFER KANAN	RINGAN	28	NORMAL	NORMAL	WILD-TYPE
D-066	RSUD PROVINSI NTB	695 86	STJ	40	PEREMPUAN	SEKOLAH DASAR	TIDAK BEKERJA	KECIL	HEMISFER KIRI	RINGAN	16	MENURUN	NORMAL	WILD-TYPE
D-067	RSUD PROVINSI NTB	664 53	LWD	51	LAKI-LAKI	SEKOLAH MENENGAH	MANUAL	KECIL	HEMISFER KANAN	RINGAN	26	NORMAL	NORMAL	WILD-TYPE
D-068	RSUD PROVINSI NTB	682 47	ADF	65	LAKI-LAKI	SEKOLAH MENENGAH	TIDAK BEKERJA	KECIL	HEMISFER KIRI	RINGAN	26	NORMAL	NORMAL	WILD-TYPE
D-069	RSUD PROVINSI NTB	710 24	KBR	50	LAKI-LAKI	SEKOLAH MENENGAH	MANUAL	KECIL	HEMISFER KANAN	RINGAN	13	MENURUN	NORMAL	WILD-TYPE
D-070	RSUD KOTA MATARAM	370 865	MYH	64	PEREMPUAN	PENDIDIKAN TINGGI	TIDAK BEKERJA	KECIL	HEMISFER KIRI	RINGAN	21	MENURUN	NORMAL	WILD-TYPE
D-071	RSUD KOTA MATARAM	307 402	ABH	55	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	HEMISFER KIRI	SEDANG	21	MENURUN	NORMAL	WILD-TYPE
D-072	RSI SITI HAJAR	112 015	ELM	57	PEREMPUAN	SEKOLAH MENENGAH	TIDAK BEKERJA	KECIL	HEMISFER KIRI	RINGAN	23	MENURUN	NORMAL	WILD-TYPE
D-073	RSI SITI HAJAR	138 037	MJP	57	LAKI-LAKI	SEKOLAH MENENGAH	NON-MANUAL	KECIL	HEMISFER KIRI	RINGAN	21	MENURUN	NORMAL	WILD-TYPE
D-074	RSI SITI HAJAR	125 513	INS	62	LAKI-LAKI	SEKOLAH MENENGAH	TIDAK BEKERJA	KECIL	HEMISFER KANAN	RINGAN	22	MENURUN	TINGGI	WILD-TYPE
D-075	RSI SITI HAJAR	140 244	MKN	56	PEREMPUAN	SEKOLAH MENENGAH	TIDAK BEKERJA	BESAR	HEMISFER KIRI	SEDANG	25	MENURUN	NORMAL	WILD-TYPE
D-076	RSI SITI	139	GPH	67	LAKI-LAKI	PENDIDIKAN	TIDAK BEKERJA	KECIL	HEMISFER	RINGAN	26	NORMAL	NORMAL	WILD-TYPE

	HAJAR	018				TINGGI			KANAN					
D-077	RSI SITI HAJAR	140 204	SLR	41	LAKI-LAKI	SEKOLAH MENENGAH	MANUAL	KECIL	BILATERAL	RINGAN	26	NORMAL	NORMAL	WILD-TYPE
D-078	RSI SITI HAJAR	139 159	SDR	50	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	HEMISFER KANAN	RINGAN	22	MENURUN	NORMAL	WILD-TYPE
D-079	RSI SITI HAJAR	138 721	ADT	50	LAKI-LAKI	SEKOLAH MENENGAH	TIDAK BEKERJA	KECIL	HEMISFER KIRI	RINGAN	23	MENURUN	NORMAL	WILD-TYPE
D-080	RSI SITI HAJAR	141 033	SRH	51	PEREMPUAN	SEKOLAH DASAR	NON-MANUAL	KECIL	HEMISFER KANAN	SEDANG	20	MENURUN	NORMAL	WILD-TYPE
D-081	RSI SITI HAJAR	141 176	SDM	53	LAKI-LAKI	SEKOLAH MENENGAH	MANUAL	KECIL	HEMISFER KIRI	SEDANG	14	MENURUN	NORMAL	WILD-TYPE
D-082	RSI SITI HAJAR	138 693	RSK	53	PEREMPUAN	SEKOLAH MENENGAH	MANUAL	KECIL	HEMISFER KIRI	RINGAN	19	MENURUN	NORMAL	WILD-TYPE
D-083	RSI SITI HAJAR	141 366	LAZ	58	LAKI-LAKI	SEKOLAH MENENGAH	MANUAL	KECIL	HEMISFER KIRI	RINGAN	24	MENURUN	NORMAL	WILD-TYPE
D-085	RSI SITI HAJAR	141 933	NKN	48	PEREMPUAN	SEKOLAH MENENGAH	TIDAK BEKERJA	KECIL	HEMISFER KIRI	RINGAN	28	NORMAL	TINGGI	WILD-TYPE
D-086	RSI SITI HAJAR	141 713	RHH	42	LAKI-LAKI	SEKOLAH MENENGAH	MANUAL	KECIL	HEMISFER KIRI	RINGAN	28	NORMAL	NORMAL	WILD-TYPE
D-087	RSI SITI HAJAR	141 725	RAE	49	PEREMPUAN	SEKOLAH MENENGAH	MANUAL	BESAR	HEMISFER KIRI	SEDANG	21	MENURUN	NORMAL	WILD-TYPE
D-088	RSI SITI HAJAR	143 488	MAH	53	LAKI-LAKI	PENDIDIKAN TINGGI	NON-MANUAL	KECIL	HEMISFER KANAN	RINGAN	26	NORMAL	NORMAL	WILD-TYPE
D-089	RSI SITI HAJAR	107 476	GBW	63	LAKI-LAKI	SEKOLAH MENENGAH	NON-MANUAL	KECIL	HEMISFER KIRI	RINGAN	23	MENURUN	NORMAL	WILD-TYPE